Steven K. Libutti, MD, FACS

Education and Training

Post-Graduate Education

• Fellow in Surgical Oncology, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 1995-96.
• Chief Resident in Surgery, Presbyterian Hospital, New York, NY 1994-95
• Resident in Surgery, Presbyterian Hospital, New York, NY 1991-94
• Intern in Surgery, Presbyterian Hospital, New York, NY 1990-91
   

Medical and Undergraduate Education

• College of Physicians & Surgeons of Columbia University, New York, NY 
  Doctor of Medicine, May 1990
• Harvard College, Harvard University, Cambridge, MA
  Bachelor of Arts in Biology, magna cum laude, June 1986
   

Academic Appointments

• William N. Hait Director, Rutgers Cancer Institute, Rutgers, The State University of New Jersey, New Brunswick, NJ 2024-Present.
• Director, Rutgers Cancer Institute, Rutgers, The State University of New Jersey, New Brunswick, NJ 2017-Present.
• Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ 2017-Present.
• Professor (Tenured), Department of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 2017-Present.
• Affiliated Distinguished Professor in Genetics, School of Arts and Sciences Department of Genetics, Rutgers, The State University of New Jersey, New Brunswick, NJ 2017-Present.
• Professor of Surgery, Uniformed Services University of the Health Sciences,
   F. Edward Hébert School of Medicine, Bethesda, MD 2007-Present.
• Professor (Tenured), Departments of Surgery and Genetics, Albert Einstein College of Medicine, Bronx, NY 2009-2017.
• Vice Chairman, Department of Surgery, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 2009-2017.
• The Marvin L. Gliedman, M.D., Distinguished Surgeon, Montefiore Medical Center, Bronx, NY 2009-2017.
• Director, Montefiore-Einstein Center for Cancer Care, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY 2009-2017.
• Associate Director, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 2009-2017.
• Director, Endocrine Tumor Program, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 2013-2017.
• Head, Tumor Angiogenesis Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2006-2009.
• Senior Investigator (Tenured), Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2006-2009.
• Investigator (Tenure Track), Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2001-2006.
• Staff Clinician, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 2000-2001.
• Senior Clinical Investigator (Commissioned Corps), Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 1999-2000.
• Clinical Investigator (Commissioned Corps), Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 1996-1999.
• Assistant Professor of Surgery, Uniformed Services University of the Health Sciences, F. Edward Hébert School of Medicine, Bethesda, MD 1996-2007.
• Clinical Associate (Commissioned Corps), Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 1995-1996.
• Administrative Chief Resident, Department of Surgery, College of Physicians & Surgeons, Columbia University, New York, NY 1994-95.
• Post-Doctoral Residency Fellow, Department of Surgery, College of Physicians & Surgeons, Columbia University, New York, NY 1990-95.
   

Hospital Staff Appointments

• Senior Vice President, Oncology Services, RWJBarnabas Health, New Brunswick, NJ 2017-Present.
• Trustee, Robert Wood Johnson University Hospital Board of Trustees, New Brunswick, NJ 2017-Present.
• Trustee, Rutgers Health Group, Inc. Board of Trustees, New Brunswick, NJ 2017-2019.
• Vice Chairman, Department of Surgery, Montefiore Medical Center, Bronx, NY 2009-2017.
• Director of Surgery, Jack D. Weiler Hospital, Montefiore Medical Center, Bronx, NY 2009-2017.
• Attending Surgeon, Walter Reed Army Medical Center, Washington, DC 2007-2010.
• Senior Staff Attending Surgeon, Clinical Center, National Institutes of Health, Bethesda, MD, 1996-2009.
• Junior Staff Fellow, Clinical Center, National Institutes of Health, Bethesda, MD, 1995-1996.

Society Memberships, Advisory Boards and Committees

• Robert H. Lurie Comprehensive Cancer Center of Northwestern University EAB 2024
• Life Sciences Alliance RBHS Advisory Board
• AACR Award for Lifetime Achievement in Cancer Research Committee
• Association of American Physicians (AAP)
• AACR Annual Meeting Clinical Trials Committee
• AACR ARPA-H Working Group
• AACR Gastric Cancer Research Grants Scientific Review Committee
• Center for COVID Response and Pandemic Preparedness (CCRP2) Scientific Advisory Board
• American Society of Gene and Cell Therapy
• VHL Alliance Clinical Advisory Council
• NCI Board of Scientific Counselors
• Rutgers Global Health Institute Core Faculty Member
• AACR Science Policy and Government Affairs (SPGA) Committee
• AACR Gastrointestinal Cancer Research Grants Scientific Review Committee
• Association of American Cancer Institutes (AACI)
• Cell & Development Biology Graduate Program, Rutgers, the State University of New Jersey
• Biochemistry Graduate Program, Rutgers, the State University of New Jersey
• AACR–Bayer Healthcare Hepatocellular Carcinoma Research Fellowship Scientific Review Committee
• Caring for Carcinoid Foundation-AACR Grant for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research Committee
• Society of Asian Academic Surgeons
• Society of Surgical Oncology, Chair, Education Council
• Neuroendocrine Cancer Awareness Network (NCAN)
• Fellow of the American College of Surgeons
• Fellow of the Society of Surgical Oncology
• American Association of Endocrine Surgeons, Past President
• International Association of Endocrine Surgeons
• Fellow of the American Surgical Association
• American Joint Committee on Cancer, Member
• American College of Surgeons’ Commission on Cancer (NCI and SEER Representative)
• Society of University Surgeons
• Society of Surgical Oncology, Chair, Technology and Communications Committee
• Society of Clinical Surgery
• Surgical Biology Club II
• Alliance for Clinical Trials in Oncology, Board of Directors
• Eastern Cooperative Oncology Group
• The Endocrine Society
• John Jones Steering Committee
• John Jones Surgical Society, President 2010-2013, Past President 2013-
• Association for Academic Surgery
• American Association for Cancer Research
• American Society of Clinical Oncology
• Society for Biological Therapy
• Society for Molecular Imaging
• The Neuroendocrine Tumor Alliance, Scientific Advisory Board (Charter Member)
• Commissioned Officers Association, Board of Directors
• Commissioned Officers Foundation, Trustee
• Reserve Officers Association
• Association of Military Surgeons of the United States
• Institutional Review Board, National Cancer Institute, Chairman
• National Cancer Institute Representative, NIH Human Subjects Research Advisory Committee
• National Cancer Institute Tumor Angiogenesis and Invasion Working Group, Co-Chairman
• Trans-Institute Angiogenesis Research Program, Executive Committee, Chair
• NIH Assembly of Scientists, elected to Executive Council
• NCI CCR Advisory Board

Honors and Awards

• Distinguished Professor, Rutgers University, 2023.
• Association of American Physicians (AAP) Inductee, 2022.
• New Jersey Health Foundation Excellence in Research Award, 2022.
• Roy A. Bowers Award for Leadership and Contributions to the Advancement of Patient Care, 2022.
• NJ Biz Health Care Power 50 (top 10), 2022.
• NJ Biz Healthcare Heroes Healthcare Professional of the Year Award, 2021.
• Edward J. Ill Excellence in Medicine Outstanding Healthcare Executive Award, 2020.
• Dr. Randy Siegel Pediatric Cancer Medical Humanitarian of the Year Award, 2020.
• SDHB Pheo-Para Coalition Science Award, 2019.
• Neuroendocrine Cancer Awareness Network Above and Beyond Award, 2018.
• Federal Laboratory Consortium Award for Excellence in Technology Transfer, 2014.
• PheoPara Alliance Science Award, 2012.
• Top Doctors New York Metro Area, 2010, 2011, 2012, 2013, 2014, 2015, 2016.
• America’s Top Doctors, 2010, 2011, 2012, 2013, 2014, 2015, 2016.
• America’s Top Doctors for Cancer, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016.
• New York Magazine’s Best Doctors in New York, 2009, 2012, 2013, 2014, 2015, 2016.
• NCI Director’s Intramural Innovation Award, 2007.
• NIH Director’s Award, 2006.
• NCI Director’s Gold Star Award, 2006.
• Federal Technology Transfer Award, 2003, 2004.
• Outstanding Service Award, Surgery Branch, National Cancer Institute, 2000.
• Blakemore Prize for Outstanding Body of Research by a Graduating Chief Resident, 1995.
• Blakemore Award for Outstanding Research in Surgery, 1991, 1992, 1993, 1994.
• First Place 2nd Annual Resident's Research Prize Competition, 1993.
• U.S. Congressional Citation for Outstanding Contributions to Medicine, 1993.
• Second Place 1st Annual Resident's Research Prize Competition, 1992.
• Allen O. Whipple Memorial Prize in Surgery, 1990.
• Samuel and Lewis Rover Award in Genetics and Development, 1990.
• Sandoz Award for Excellence in Biomedical Research, 1990.
• Alpha Omega Alpha Medical Honor Society, elected in 1990.
• William Gerety Cup, Intramural Athletics, 1986.
• John Harvard Scholarship for Excellence in Academics, 1985.
• Harvard College Scholarship for Excellence in Academics, 1983, 1984.

Uniformed Service Awards

• Commissioned Corps USPHS, Commendation Medal.
• Commissioned Corps USPHS, Outstanding Unit Citation.
• Commissioned Corps USPHS, Crisis Response Service Award.
• Department of Defense, National Defense Service Medal.
• Department of Defense, Global War on Terrorism Service Medal.
• Commissioned Corps USPHS, Commissioned Corps Training Ribbon.
• Commissioned Corps, USPHS, Field Medical Readiness Badge.

Editorial Boards

• Cancer Gene Therapy, Editor-in-Chief Emeritus 2020 - Present
• Cancer Gene Therapy, Editor-in-Chief 2014 – 2019
• Translational Cancer Research
• Endocrine Related Cancer
• Journal of Immunotherapy
• Annals of Surgical Oncology, Section Editor 2016-2021
• Journal of Surgical Oncology, Section Editor
• Journal of Translational Medicine, Associate Editor
• Molecular Cancer, Associate Editor
• Surgery, Society Editor 2008-2011

Journal and Grant Review Boards (Ad Hoc)

• Cancer
• Journal of the National Cancer Institute
• The British Journal of Surgery
• The American Journal of Pathology
• Cancer Research
• Cancer Research UK
• Clinical Cancer Research
• National Institutes of Health SBIR Study Section Sub-Group
• The Dutch Cancer Society
• The National Cancer Institute of Canada
• Microvascular Research

Current Research Support

• • 5P30CA072720-25   Libutti (PI)   03/01/2024 - 02/29/2029
  NCI/NIH Cancer Center Support Grant (CCSG) - Supports programs and core resources for the NCI-designated Comprehensive Cancer Center.
  NIH/NCI
  Total Support: $20,945,581

  • 3P30CA072720-25S2   Libutti (PI)   03/01/2024 - 02/28/2025 
  Scholars and Early-Stage Investigator Advancement Initiative (SEA)
  NCI/NIH
  Total Support: $200,000

  • 3P30CA072720-25S1   Libutti (Contact PI)    03/01/2024 - 02/28/2026 
  2024 NCI Early Career Cancer Clinical Investigator Award (ECIA)
  NCI/NIH
  Total Support: $120,000

  • 5R01CA240516-03     Libutti (MPI)    03/15/2020 - 02/28/2025
  “Designing a transcriptome-based, targeted theranostic platform for prostate cancer”
  NIH/NCI
  Total Support: $1,770,900

  • The MacMillan Family Foundation, Inc.   Libutti (PI)      06/01/2020 – 03/31/2026
  Cancer Immunology and Metabolism Center of Excellence – New Recruited or Focused Center PIs 
  Research Gift Total Support: $25,000,000

  • Peterson Accelerator Award     Libutti (PI)     01/03/2020 - 01/02/2025
  “The role of the B7x pathway in the progression of neuroendocrine tumors”    
  Neuroendocrine Tumor Research Foundation (NETRF) 
  Total Support: $1,200,000

  • 1R01CA247652-01A1     MPI (Libutti)(Contact PI Zamboni)    04/01/2021 - 03/31/2026 Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer Tumors.
  NIH
  Total Support: $2,792,913 ($837,975 Rutgers Cancer Institute)

  • Amick Family Funding Neuroendocrine Research    Libutti (PI)    10/31/2018 - 10/30/2024
  Nancy Scott Amick Memorial Laboratory for Cancer Research 
  Research Gift Total Support: $600,000
   

  Completed Research Support

  • 1U01HL150852-01         Libutti (MPI)       09/23/2019 - 07/31/2024
  Rutgers Optimizes Innovation (ROI) – “Program will provide a vertically integrated mechanism to uncover promising biomedical product discoveries and guide the innovator through the commercialization process”    
  NIH/NHLBI
  Total Support: $4,443,596

  • 3P30CA072720-23S1         Libutti (PI)         03/01/2021 - 02/28/2024 
  T Cell Receptor Discovery for Engineered T-cell Therapy for Human Cancers.
  NCI/NIH
  Total Support: $4,522,492

  • NexImmune Collaboration      Libutti (PI)       02/01/2022 - 01/31/2024
  To develop novel immunotherapy for targeting immune checkpoint proteins in the neuroendocrine tumors.
  NexImmune
  Total Support: $247,000

  •1R01HL141934-04            Libutti (co-PI)    (Lai PI)    05/01/2018 - 04/30/2023
  “Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics”    
  NIH
  Total Support: $2,658,480

  • 3P30CA072720-22S3        Libutti (PI)        03/01/2021 - 02/28/2024
  NCI/NIH Cancer Center Support Grant (CCSG) Supplement – Immune Radiation Response Index (i-RRI) for Immune Cells from Normal and Tumor Microenvironments
  NIH/NCI
  Total Support: $126,300

  • 3P30CA072720-21S2        Libutti (PI)        03/01/2020 - 02/28/2023
  NCI/NIH Cancer Center Support Grant (CCSG) Supplement – Study to determine patterns of low HPV vaccine uptake, role of vaccine hesitancy, VHPs’ decision-making and potential acceptability of messaging, information sources and delivery channels to reduce hesitancy.
  NIH/NCI
  Total Support: $199,728

  • 3P30CA072720-21S4        Libutti (PI)       03/01/2020 - 02/28/2023
  NCI/NIH Cancer Center Support Grant (CCSG) Supplement – Expand and integrate TDP’s clinical services throughout CINJ. With the ongoing COVID-19 pandemic, this will include introducing virtual tobacco treatment groups and telehealth visits.
  NIH/NCI
  Total Support: $390,587

  • 3P30CA072720-22S2        Libutti (PI)        03/01/2021 - 02/28/2023
  NCI/NIH Cancer Center Support Grant (CCSG) Supplement – Initiative to develop processes across NCI-supported Cancer Centers and community sites that can be deployed in support of NCI-sponsored network studies.
  NIH/NCI
  Total Support: $300,000

  • RWJ Foundation 74673        Libutti (PI)        08/01/2017 - 01/31/2021
  Supporting a federal-state collaboration to foster new clinical trials for cancer therapies in New Jersey.
  Total Support: $2,000,000

  • 261201600031C-0-0-1 (NCE)    Libutti (Co-PI)        09/01/2015-09/30/2019 “SynVivo-Tumor: A Physiological 3D model of the Tumor Microenvironment”
  CFDRC
  Total Support: $63,016

  • DOD W81XWH-15-1-0369        Libutti (PI)        09/30/2015-09/29/2019
  “FILIP1L inhibits ovarian cancer metastasis through inhibition of WNT signaling”
  Total Support: $757,477

  • 4P30CA072720-19S6        Libutti (PI)       03/01/97-02/28/19
  Cancer Center Support Grant (CCSG) - Supports programs and core resources for the NCI-designated Comprehensive Cancer Center.
  Total Support: $2,651,316

  • 4P30CA072720-19S5        Libutti (PI)        09/01/15-02/28/19
  Cancer Center Support Grant Supplement – Community Health Educators (CHEs)
  Total Support: $125,000

  • 7R01CA170911-07    Libutti (MPI)        09/01/12-06/30/18
  “Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis”
  NCI Provocative Questions RFA
  Total Support: $1,732,625

  • 3R01CA170911-07S1       Libutti (MPI)       08/01/17-06/30/18
  NCI/NIH
  “Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis”
  Supplement
  Total Support: $45,916

  • P50CA174521          Libutti (PI)        09/01/16-02/28/18
  Pilot Grant from University of Iowa NET SPORE
  “Development of a Novel Immune-Checkpoint Inhibitor: B7x Blockade in Neuroendocrine Tumors (NETs)”
  Total Support: $50,000

  • T32CA200561        Libutti (PI)       12/01/15-11/30/20
  “Training of Surgeons for Studies of the Tumor Microenvironment”
  Total Requested Support: $1,352,720

  • R01DK079970    Libutti (co-PI) (Levine PI)    09/22/12-06/30/16
  “The role of GCM2 in parathyroid gland homeostasis”
  Total Support: $235,524

  • P50CA174521       Libutti (PI)       09/01/15-08/31/16
  Pilot Grant from University of Iowa NET SPORE
  Characterization of new B7 immune-checkpoints in the tumor microenvironment of human carcinoid and pancreatic neuroendocrine tumors.
  Total Support: $50,000

  • U54CA151668 8847      Libutti (PI)        09/01/10-08/31/16
  “Multifunctional Nanoassemblies for Ligand-Directed Imaging and Therapy of Endocrine Tumors of the Pancreas”
  Total Support: $710,370

  • Linda and Earle Altman    Libutti (PI)       06/01/10-06/30/15
  “Studies of the tumor microenvironment and tumor associated vasculature”
  Unrestricted research gift.
  Total Support: $1,250,000

  • 2012 Caring for Carcinoid Foundation-AACR Grant for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research    Pasqualini (Libutti Co-PI)    07/01/12-06/30/14
  “Octreotide-targeted treatment of neuroendocrine tumors of the pancreas”
  Total Support: $250,000

  • Speracura, LLC    Libutti (PI)        09/20/10-09/19/13
  Endocrine/Neuroendocrine Tumor Program 
  Total Support: $330,000

  • Pheo/Para Alliance      Libutti (PI)      07/01/11-07/01/13
  “Genomic profiling of pheochromocytomas”
  Total Support: $75,000

  • AECC - Pilot Project Grant   Libutti (PI)     03/01/11-02/28/12
  “To discover novel pathways involved in the formation of endocrine tumors using high throughput genomic approaches”
  Total Support:  $15,000

  • AECOM – Dean’s Pilot Grant    Libutti (PI)     06/01/11-05/31/12
  “Understanding the formation of endocrine tumors using high throughput global RNA massively-parallel sequencing”
  Total Support: $15,000
  • NCI - Z01 SC 010368    Libutti (PI)    10/01/01-06/30/09  “Targeting the Tumor Vasculature to Treat Cancer”
  NCI Tenured Intramural Scientist: novel approaches to the targeted therapy of cancer.
  Total Support: $7,200,000

  • Alliance     Libutti (Site PI)
  American College of Surgeons Oncology Group, cooperative clinical trials in cancer.  Sponsored by the National Cancer Institute.    

  Patents

  • Bass LS, Libutti SK, Eaton AM, Tissue bonding and sealing composition and methods of using the same, U. S. Patent 5,209,776
  • Bass LS, Libutti SK, Eaton AM, Tissue bonding and sealing composition and methods of using the same, U.S. Patent 5,292,362.
  • Stern D, Clauss M, Kao J, Kayton ML, Libutti SK, Antibody which specifically binds to endothelial monocyte activating polypeptide II, U.S. Patent 5,641,867.
  • Stern D, Clauss M, Kao J, Kayton ML, Libutti SK, Endothelial monocyte activating polypeptide II: a mediator which activates host response, U.S. Patent 6,228,837.
  • Stern D, Clauss M, Kao J, Kayton ML, Libutti SK, Endothelial monocyte activating polypeptide II: a mediator which activates host response, U.S. Patent 6,734,168.
  • Libutti SK, Zeiger MA, Mazzanti C, Umbricht C, Diagnostic tool for diagnosing benign versus malignant thyroid lesions, U.S. Patent 7,901,881.
  • Libutti SK, Kwon M, Tandle A, FILIPIL compositions and methods for treating cancer, U.S. Patent 8,501,912.
  • Libutti SK, He M, Molecular-based method of cancer diagnosis and prognosis, U.S. Patent 8,715,928.
  • Libutti SK, He M, Molecular-based method of cancer diagnosis and prognosis, U.S. Patent 9,181,589.
  • Libutti SK, Zeiger MA, Prasad NB, Umbricht C, Diagnostic tool for diagnosing benign versus malignant thyroid lesions, U.S. Patent 9,234,244.
  • Libutti SK, Kwon M, Tandle A, FILIPIL nucleic acid fragments, U.S. Patent 9,279,009.

Peer-Reviewed Publications

1. Libutti, S. K., Oz, M. C., Forde, K. A., Auteri, J. S., Johnson, J. P., Bass, L. S., and Treat, M. R. Canine colonic anastomoses reinforced with dye-enhanced fibrinogen and a diode laser. Surg Endosc, 4: 97-99, 1990.

2. Libutti, S. K., Oz, M. C., Chuck, R. S., Auteri, J. S., Treat, M. R., and Nowygrod, R. A preliminary study of dye-enhanced laser photosclerosis. Surgery, 109: 163-168, 1991.

3. Wider, T. M., Libutti, S. K., Greenwald, D. P., Oz, M. C., Yager, J. S., Treat, M. R., and Hugo, N. E. Skin closure with dye-enhanced laser welding and fibrinogen. Plast Reconstr Surg, 88: 1018-1025, 1991.

4. Ashton, R. C., Jr., Libutti, S. K., Oz, M. C., Lontz, J. F., Lemole, G. M., Jr., and Lemole, G. M. The effects of laser-assisted fibrinogen bonding on suture material. J Surg Res, 53: 39-42, 1992.

5. Bass, L. S., Oz, M. C., Libutti, S. K., and Treat, M. R. Alternative wavelengths for sutureless laser microvascular anastomosis: a preliminary study on acute samples. J Clin Laser Med Surg, 10: 207-210, 1992.

6. Oz, M. C., Williams, M. R., Moscarelli, R., Libutti, S. K., Kaynar, M., Fras, C. I., Treat, M. R., and Nowygrod, R. Laser bonding of secondary bronchi with solvent--detergent-treated cryoprecipitate. J Clin Laser Med Surg, 10: 105-107, 1992.

7. Oz, M. C., Libutti, S. K., Ashton, R. C., Lontz, J. F., Lemole, G. M., and Nowygrod, R. Comparison of laser-assisted fibrinogen-bonded and sutured canine arteriovenous anastomoses. Surgery, 112: 76-83, 1992.

8. Bass, L. S., Libutti, S. K., Oz, M. C., Rosen, J., Williams, M. R., Nowygrod, R., and Treat, M. R. Canine choledochotomy closure with diode laser-activated fibrinogen solder. Surgery, 115: 398-401, 1994.

9. Kao, J., Houck, K., Fan, Y., Haehnel, I., Libutti, S. K., Kayton, M. L., Grikscheit, T., Chabot, J., Nowygrod, R., Greenberg, S., and et al. Characterization of a novel tumor-derived cytokine. Endothelial- monocyte activating polypeptide II. J Biol Chem, 269: 25106-25119, 1994.

10. Kirsch, A. J., Dean, G. E., Oz, M. C., Libutti, S. K., Treat, M. R., Nowygrod, R., and Hensle, T. W. Preliminary results of laser tissue welding in extravesical reimplantation of the ureters. J Urol, 151: 514-517, 1994.

11. Libutti, S. K. and Starker, P. M. Laparoscopic resection of a nonparasitic liver cyst. Surg Endosc, 8: 1105-1107, 1994.

12. Downey, R. J., Libutti, S. K., Gorenstein, L., and Mercer, S. Airway management during retrieval of the very large aspirated foreign body: a method for the flexible bronchoscope. Anesth Analg, 81: 186-187, 1995.

13. Kirsch, A. J., Chang, D. T., Kayton, M. L., Newhouse, J., Libutti, S. K., Treat, M. R., Connor, J. P., and Hensle, T. W. Sutureless rabbit bladder mucosa patch graft urethroplasty using diode laser and solder. J Urol, 153: 1303-1307, 1995.

14. Kirsch, A. J., Chang, D. T., Kayton, M. L., Libutti, S. K., Connor, J. P., and Hensle, T. W. Effects of diode laser welding with dye-enhanced glue on tensile strength of sutures commonly used in urology. Lasers Surg Med, 18: 167-170, 1996.

15. Kirsch, A. J., Chang, D. T., Kayton, M. L., Libutti, S. K., Treat, M. R., and Hensle, T. W. Laser welding with albumin-based solder: experimental full-tubed skin graft urethroplasty. Lasers Surg Med, 18: 225-230, 1996.

16. Marvin, M. R., Libutti, S. K., Kayton, M., Kao, J., Hayward, J., Grikscheit, T., Fan, Y., Brett, J., Weinberg, A., Nowygrod, R., LoGerfo, P., Feind, C., Hansen, K. S., Schwartz, M., Stern, D., and Chabot, J. A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. J Surg Res, 63: 248-255, 1996.

17. Bartlett, D. L., Ma, G., Alexander, H. R., Libutti, S. K., and Fraker, D. L. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer, 80: 2084-2090, 1997.

18. Brown, C. K., Bartlett, D. L., Doppman, J. L., Gorden, P., Libutti, S. K., Fraker, D. L., Shawker, T. H., Skarulis, M. C., and Alexander, H. R. Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas. Surgery, 122: 1189-1193; discussion 1193-1184, 1997.

19. Libutti, S. K., Bartlett, D. L., Jaskowiak, N. T., Skarulis, M., Marx, S. J., Spiegel, A. M., Fraker, D. L., Doppman, J. L., Shawker, T. J., and Alexander, H. R. The role of thyroid resection during reoperation for persistent or recurrent hyperparathyroidism. Surgery, 122: 1183-1187; discussion 1187-1188, 1997.

20. Ma, G. Y., Bartlett, D. L., Reed, E., Figg, W. D., Lush, R. M., Lee, K. B., Libutti, S. K., and Alexander, H. R. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am, 3: 174-179, 1997.

21. Riker, A., Libutti, S. K., and Bartlett, D. L. Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol, 6: 157-169, 1997.

22. Alexander, H. R., Bartlett, D. L., Venzon, D. J., Libutti, S. K., Doppman, J. L., Fraker, D. L., Norton, J. A., Gibril, F., and Jensen, R. T. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome. Surgery, 124: 1160-1166, 1998.

23. Alexander, H. R., Brown, C. K., Bartlett, D. L., Libutti, S. K., Figg, W. D., Raje, S., and Turner, E. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. Clin Cancer Res, 4: 2357-2362, 1998.

24. Alexander, H. R., Jr., Bartlett, D. L., Libutti, S. K., Fraker, D. L., Moser, T., and Rosenberg, S. A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol, 16: 1479-1489, 1998.

25. Alexander, H. R., Jr., Bartlett, D. L., and Libutti, S. K. Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J Sci Am, 4: 2-11, 1998.

26. Bartlett, D. L., Buell, J. F., Libutti, S. K., Reed, E., Lee, K. B., Figg, W. D., Venzon, D. J., and Alexander, H. R. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis [published erratum appears in Cancer 1998 Nov 15;83(10):2241]. Cancer, 83: 1251-1261, 1998.

27. Doppman, J. L., Skarulis, M. C., Chang, R., Alexander, H. R., Bartlett, D., Libutti, S. K., Marx, S. J., and Spiegel, A. M. Hypocalcemic stimulation and nonselective venous sampling for localizing parathyroid adenomas: work in progress. Radiology, 208: 145-151, 1998.

28. Libutti, S. K., Choyke, P. L., Bartlett, D. L., Vargas, H., Walther, M., Lubensky, I., Glenn, G., Linehan, W. M., and Alexander, H. R. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery, 124: 1153-1159, 1998.

29. Lubensky, I. A., Pack, S., Ault, D., Vortmeyer, A. O., Libutti, S. K., Choyke, P. L., Walther, M. M., Linehan, W. M., and Zhuang, Z. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol, 153: 223-231, 1998.

30. Park, B. J., Alexander, H. R., Libutti, S. K., Huang, J., Royalty, D., Skarulis, M. C., Jensen, R. T., Gorden, P., Doppman, J. L., Shawker, T. H., Fraker, D. L., Norton, J. A., and Bartlett, D. L. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery, 124: 1056-1061; discussion 1061-1052, 1998.

31. Berger, A. C., Libutti, S. K., Bartlett, D. L., Skarulis, M. G., Marx, S. J., Spiegel, A. M., Doppman, J. L., and Alexander, H. R. Heterogeneous gland size in sporadic multiple gland parathyroid hyperplasia. J Am Coll Surg, 188: 382-389, 1999.

32. Berger, A. C., Buell, J. F., Venzon, D., Baker, A. R., and Libutti, S. K. Management of symptomatic malignant melanoma of the gastrointestinal tract [see comments]. Ann Surg Oncol, 6: 155-160, 1999.

33. Cho, H. K., Lush, R. M., Bartlett, D. L., Alexander, H. R., Wu, P. C., Libutti, S. K., Lee, K. B., Venzon, D. J., Bauer, K. S., Reed, E., and Figg, W. D. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol, 39: 394-401, 1999.

34. Desai, S. B. and Libutti, S. K. Tumor angiogenesis and endothelial cell modulatory factors [see comments]. J Immunother, 22: 186-211, 1999.

35. Feldman, A. L., Sharaf, R. N., Skarulis, M. C., Bartlett, D. L., Libutti, S. K., Weinstein, L. S., Marx, S. J., Norton, J. A., Fraker, D. L., and Alexander, H. R. Results of heterotopic parathyroid autotransplantation: a 13-year experience. Surgery, 126: 1042-1048, 1999.

36. Feldman, A. L., Alexander, H. R., Jr., Bartlett, D. L., Fraker, D. L., and Libutti, S. K. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma [see comments]. Ann Surg Oncol, 6: 562-567, 1999.

37. Gnant, M. F., Noll, L. A., Terrill, R. E., Wu, P. C., Berger, A. C., Nguyen, H. Q., Lans, T. E., Flynn, B. M., Libutti, S. K., Bartlett, D. L., and Alexander, H. R., Jr. Isolated hepatic perfusion for lapine liver metastases: impact of hyperthermia on permeability of tumor neovasculature. Surgery, 126: 890-899, 1999.

38. Gnant, M. F., Berger, A. C., Huang, J., Puhlmann, M., Wu, P. C., Merino, M. J., Bartlett, D. L., Alexander, H. R., Jr., and Libutti, S. K. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res, 59: 4668-4674, 1999.

39. Libutti, S. K., Alexander, H. R., Bartlett, D. L., Sampson, M. L., Ruddel, M. E., Skarulis, M., Marx, S. J., Spiegel, A. M., Simmonds, W., and Remaley, A. T. Kinetic analysis of the rapid intraoperative parathyroid hormone assay in patients during operation for hyperparathyroidism. Surgery, 126: 1145-1150; discussion 1150-1141, 1999.

40. Libutti, S. K., Choyke, P., Carrasquillo, J. A., Bacharach, S., and Neumann, R. D. Monitoring responses to antiangiogenic agents using noninvasive imaging tests [In Process Citation]. Cancer J Sci Am, 5: 252-256, 1999.

41. Park, B. J., Alexander, H. R., Libutti, S. K., Wu, P., Royalty, D., Kranda, K. C., and Bartlett, D. L. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol, 6: 582-590, 1999.

42. Walther, M. M., Lyne, J. C., Libutti, S. K., and Linehan, W. M. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology, 53: 496-501, 1999.

43. Wu, P. C., McCart, A., Hewitt, S. M., Turner, E., Libutti, S. K., Bartlett, D. L., and Alexander, H. R. Isolated organ perfusion does not result in systemic microembolization of tumor cells [see comments]. Ann Surg Oncol, 6: 658-663, 1999.

44. Wu, P. C., Alexander, H. R., Huang, J., Hwu, P., Gnant, M., Berger, A. C., Turner, E., Wilson, O., and Libutti, S. K. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)- alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res, 59: 205-212, 1999.

45. Zeh, H., Choyke, P. L., Alexander, H. R., Bartlett, D. L., Libutti, S. K., Chang, R., and Summers, R. M. Gadolinium-enhanced 3D MRA prior to isolated hepatic perfusion for metastases. J Comput Assist Tomogr, 23: 664-669, 1999.

46. Alexander, H. R., Libutti, S. K., Bartlett, D. L., Puhlmann, M., Fraker, D. L., and Bachenheimer, L. C. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver [In Process Citation]. Clin Cancer Res, 6: 3062-3070, 2000.

47. Alexander, H. R., Jr., Bartlett, D. L., and Libutti, S. K. Current Status of Isolated Hepatic Perfusion With or Without Tumor Necrosis Factor for the Treatment of Unresectable Cancers Confined to Liver. Oncologist, 5: 416-424, 2000.

48. Bacharach, S. L., Libutti, S. K., and Carrasquillo, J. A. Measuring tumor blood flow with H(2)(15)O: practical considerations. Nucl Med Biol, 27: 671-676, 2000.

49. Berger, A. C., Feldman, A. L., Gnant, M. F., Kruger, E. A., Sim, B. K., Hewitt, S., Figg, W. D., Alexander, H. R., and Libutti, S. K. The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing. J Surg Res, 91: 26-31, 2000.

50. Berger, A. C., Alexander, H. R., Tang, G., Wu, P. S., Hewitt, S. M., Turner, E., Kruger, E., Figg, W. D., Grove, A., Kohn, E., Stern, D., and Libutti, S. K. Endothelial Monocyte Activating Polypeptide II Induces Endothelial Cell Apoptosis and May Inhibit Tumor Angiogenesis. Microvasc Res, 60: 70-80, 2000.

51. Berger, A. C., Alexander, H. R., Wu, P. C., Tang, G., Gnant, M. F., Mixon, A., Turner, E. S., and Libutti, S. K. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II). Cytokine, 12: 992-1000, 2000.

52. Berger, A. C., Tang, G., Alexander, H. R., and Libutti, S. K. Endothelial monocyte-activating polypeptide II, a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis [In Process Citation]. J Immunother, 23: 519-527, 2000.

53. Feingold, D. L., Alexander, H. R., Chen, C. C., Libutti, S. K., Shawker, T. H., Simonds, W. F., Marx, S. J., Skarulis, M. C., Doppman, J. L., Schrump, D. S., and Bartlett, D. L. Ultrasound and sestamibi scan as the only preoperative imaging tests in reoperation for parathyroid adenomas. Surgery, 128: 1103-1110, 2000.

54. Feldman, A. L. and Libutti, S. K. Correspondence re: Q-R. Chen et al., Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res., 59: 3308-3312, 1999 [letter] [In Process Citation]. Cancer Res, 60: 1463-1464, 2000.

55. Feldman, A. L., Restifo, N. P., Alexander, H. R., Bartlett, D. L., Hwu, P., Seth, P., and Libutti, S. K. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice [In Process Citation]. Cancer Res, 60: 1503-1506, 2000.

56. Feldman, A. L. and Libutti, S. K. Progress in antiangiogenic gene therapy of cancer [In Process Citation]. Cancer, 89: 1181-1194, 2000.

57. Feldman, A. L., Tamarkin, L., Paciotti, G. F., Simpson, B. W., Linehan, W. M., Yang, J. C., Fogler, W. E., Turner, E. M., Alexander, H. R., Jr., and Libutti, S. K. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.[In Process Citation]. Clin Cancer Res, 6: 4628-4634, 2000.

58. Hirshberg, B., Livi, A., Bartlett, D. L., Libutti, S. K., Alexander, H. R., Doppman, J. L., Skarulis, M. C., and Gorden, P. Forty-eight-hour fast: the diagnostic test for insulinoma [In Process Citation]. J Clin Endocrinol Metab, 85: 3222-3226, 2000.

59. Kershaw, M. H., Westwood, J. A., Zhu, Z., Witte, L., Libutti, S. K., and Hwu, P. Generation of Gene-Modified T Cells Reactive against the Angiogenic Kinase Insert Domain-Containing Receptor (KDR) Found on Tumor Vasculature. Hum Gene Ther, 11: 2445-2452, 2000.

60. Kruger, E. A., Duray, P. H., Tsokos, M. G., Venzon, D. J., Libutti, S. K., Dixon, S. C., Rudek, M. A., Pluda, J., Allegra, C., and Figg, W. D. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun, 268: 183-191, 2000.

61. Kurdziel, K., Bacharach, S., Carrasquillo, J., Huebsch, S., Whatley, M., Sellers, D., Steinberg, S., Libutti, S., Pluda, J., Reed, E., Dahut, W., and Figg, W. 8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide. Clin Positron Imaging, 3: 144, 2000.

62. Libutti, S. K., Barlett, D. L., Fraker, D. L., and Alexander, H. R. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies [In Process Citation]. J Am Coll Surg, 191: 519-530, 2000.

63. Libutti, S. K., Choyke, P. L., Alexander, H. R., Glenn, G., Bartlett, D. L., Zbar, B., Lubensky, I., McKee, S. A., Maher, E. R., Linehan, W. M., and Walther, M. M. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery, 128: 1022-1027;discussion 1027-1028, 2000.

64. Lodge, M. A., Carson, R. E., Carrasquillo, J. A., Whatley, M., Libutti, S. K., and Bacharach, S. L. Parametric images of blood flow in oncology PET studies using [15O]water [In Process Citation]. J Nucl Med, 41: 1784-1792, 2000.

65. McCart, J. A., Puhlmann, M., Lee, J., Hu, Y., Libutti, S. K., Alexander, H. R., and Bartlett, D. L. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression [In Process Citation]. Gene Ther, 7: 1217-1223, 2000.

66. Mohr, V. H., Vortmeyer, A. O., Zhuang, Z., Libutti, S. K., Walther, M. M., Choyke, P. L., Zbar, B., Linehan, W. M., and Lubensky, I. A. Histopathology and Molecular Genetics of Multiple Cysts and Microcystic (Serous) Adenomas of the Pancreas in von Hippel-Lindau Patients. Am J Pathol, 157: 1615-1621, 2000.

67. Puhlmann, M., Brown, C. K., Gnant, M., Huang, J., Libutti, S. K., Alexander, H. R., and Bartlett, D. L. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther, 7: 66-73, 2000.

68. Said, B., McCart, J. A., Libutti, S. K., and Choyke, P. L. Ferumoxide-enhanced MRI in patients with colorectal cancer and rising CEA: surgical correlation in early recurrence. Magn Reson Imaging, 18: 305-309, 2000.

69. Walther, M. C., Shawker, T. H., Libutti, S. K., Lubensky, I., Choyke, P. L., Venzon, D., and Linehan, W. M. A Phase 2 Study of Radio Frequency Interstitial Tissue Ablation of Localized Renal Tumors. J Urol, 163: 1424-1427, 2000.

70. Bartlett, D. L., Libutti, S. K., Figg, W. D., Fraker, D. L., and Alexander, H. R. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery, 129: 176-187., 2001.

71. Berger, A. C., Gibril, F., Venzon, D. J., Doppman, J. L., Norton, J. A., Bartlett, D. L., Libutti, S. K., Jensen, R. T., and Alexander, H. R. Prognostic value of initial fasting serum gastrin levels in patients with zollinger-ellison syndrome. J Clin Oncol, 19: 3051-3057., 2001.

72. Chang, E., Alexander, H. R., Libutti, S. K., Hurst, R., Zhai, S., Figg, W. D., and Bartlett, D. L. Laparoscopic continous hyperthermic peritoneal perfusion. J Am Coll Surg, 193: 225-229., 2001.

73. Crabtree, J. S., Scacheri, P. C., Ward, J. M., Garrett-Beal, L., Emmert-Buck, M. R., Edgemon, K. A., Lorang, D., Libutti, S. K., Chandrasekharappa, S. C., Marx, S. J., Spiegel, A. M., and Collins, F. S. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A, 98: 1118-1123., 2001.

74. Feldman, A. L., Pak, H., Yang, J. C., Alexander, H. R., Jr., and Libutti, S. K. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer, 91: 1525-1529., 2001.

75. Feldman, A. L., Alexander, H. R., Hewitt, S. M., Lorang, D., Thiruvathukal, C. E., Turner, E. M., and Libutti, S. K. Effect of Retroviral Endostatin Gene Transfer on Subcutaneous and Intraperitoneal Growth of Murine Tumors. J Natl Cancer Inst, 93: 1014-1020., 2001.

76. Feldman, A. L., Alexander, H. R., Jr., Bartlett, D. L., Kranda, K. C., Miller, M. S., Costouros, N. G., Choyke, P. L., and Libutti, S. K. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol, 8: 741-745., 2001.

77. Hirshberg, B., Alexander, H. R., Bartlett, D. L., Skarulis, M. C., Libutti, S. K., and Gorden, P. Nesidioblastosis in adults: a clinical enigma(g). J Clin Endocrinol Metab, 86: 2329., 2001.

78. Kayton, M. L. and Libutti, S. K. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature. Curr Opin Investig Drugs, 2: 136-138., 2001.

79. Kivlen, M. H., Bartlett, D. L., Libutti, S. K., Skarulis, M. C., Marx, S. J., Simonds, W. F., Weinstein, L. S., Jensen, R. T., McCart, J. A., Naik, A. M., Kranda, K. C., Brennan, M. F., Norton, J. A., Fraker, D. L., and Alexander, H. R. Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery, 130: 991-998., 2001.

80. Lans, T. E., Bartlett, D. L., Libutti, S. K., Gnant, M. F., Liewehr, D. J., Venzon, D. J., Turner, E. M., and Alexander, H. R. Role of Tumor Necrosis Factor on Toxicity and Cytokine Production after Isolated Hepatic Perfusion. Clin Cancer Res, 7: 784-790., 2001.

81. Libutti, S. K., Alexander, H. R., Jr., Choyke, P., Bartlett, D. L., Bacharach, S. L., Whatley, M., Jousse, F., Eckelman, W. C., Kranda, K., Neumann, R. D., and Carrasquillo, J. A. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol, 8: 779-786, 2001.

82. McCart, J. A., Ward, J. M., Lee, J., Hu, Y., Alexander, H. R., Libutti, S. K., Moss, B., and Bartlett, D. L. Systemic Cancer Therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes. Cancer Res, 61: 8751-8757., 2001.

83. Riddell, C., Carson, R. E., Carrasquillo, J. A., Libutti, S. K., Danforth, D. N., Whatley, M., and Bacharach, S. L. Noise reduction in oncology fdg pet images by iterative reconstruction: a quantitative assessment. J Nucl Med, 42: 1316-1323., 2001.

84. Watabe, H., Channing, M. A., Riddell, C., Jousse, F., Libutti, S. K., Carrasquillo, J. A., Bacharach, S. L., and Carson, R. E. Noninvasive estimation of the aorta input function for measurement of tumor blood flow with. IEEE Trans Med Imaging, 20: 164-174., 2001.

85. Zogakis, T. G. and Libutti, S. K. General aspects of anti-angiogenesis and cancer therapy. Expert Opin Biol Ther, 1: 253-275., 2001.

86. Zogakis, T. G., Bartlett, D. L., Libutti, S. K., Liewehr, D. J., Steinberg, S. M., Fraker, D. L., and Alexander, H. R. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol, 8: 771-778, 2001.

87. Albright, S. V., McCart, J. A., Libutti, S. K., Bartlett, D. L., Alexander, H. R., Sampson, M. L., Ruddel, M. E., and Remaley, A. T. Rapid measurement of insulin using the Abbott IMx: application to the management of insulinoma. Ann Clin Biochem, 39: 513-515, 2002.

88. Alexander, H. R., Jr., Libutti, S. K., Bartlett, D. L., Pingpank, J. F., Kranda, K., Helsabeck, C., and Beresnev, T. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer, 95: 730-736, 2002.

89. Calvo, A., Feldman, A. L., Libutti, S. K., and Green, J. E. Adenovirus-mediated Endostatin Delivery Results in Inhibition of Mammary Gland Tumor Growth in C3(1)/SV40 T-Antigen Transgenic Mice. Cancer Res, 62: 3934-3938, 2002.

90. Calvo, A., Yokoyama, Y., Smith, L. E., Ali, I., Shih, S. C., Feldman, A. L., Libutti, S. K., Sundaram, R., and Green, J. E. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer, 101: 224-234, 2002.

91. Choyke, P. L., Knopp, M. V., and Libutti, S. K. Special techniques for imaging blood flow to tumors. Cancer J, 8: 109-118, 2002.

92. Costouros, N. G., Diehn, F. E., and Libutti, S. K. Molecular imaging of tumor angiogenesis. J Cell Biochem Suppl, 39: 72-78, 2002.

93. Costouros, N. G., Lorang, D., Zhang, Y., Miller, M. S., Diehn, F. E., Hewitt, S. M., Knopp, M. V., Li, K. C., Choyke, P. L., Alexander, H. R., and Libutti, S. K. Microarray gene expression analysis of murine tumor heterogeneity defined by dynamic contrast-enhanced MRI. Mol Imaging, 1: 301-308, 2002.

94. Diehn, F. E., Costouros, N. G., Miller, M. S., Feldman, A. L., Alexander, H. R., Li, K. C., and Libutti, S. K. Noninvasive fluorescent imaging reliably estimates biomass in vivo. Biotechniques, 33: 1250-1252, 1254-1255, 2002.

95. Elaraj, D. M., Remaley, A. T., Simonds, W. F., Skarulis, M. C., Libutti, S. K., Bartlett, D. L., Venzon, D. J., Marx, S. J., and Alexander, H. R. Utility of rapid intraoperative parathyroid hormone assay to predict severe postoperative hypocalcemia after reoperation for hyperparathyroidism. Surgery, 132: 1028-1034, 2002.

96. Feldman, A. L., Friedl, J., Lans, T. E., Libutti, S. K., Lorang, D., Miller, M. S., Turner, E. M., Hewitt, S. M., and Alexander, H. R. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer, 99: 149-153, 2002.

97. Feldman, A. L., Alexander, H. R., Jr., Yang, J. C., Linehan, W. M., Eyler, R. A., Miller, M. S., Steinberg, S. M., and Libutti, S. K. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer, 95: 1637-1643, 2002.

98. Feldman, A. L., Costouros, N. G., Wang, E., Qian, M., Marincola, F. M., Alexander, H. R., and Libutti, S. K. Advantages of mRNA amplification for microarray analysis. Biotechniques, 33: 906-912, 914, 2002.

99. Friedl, J., Puhlmann, M., Bartlett, D. L., Libutti, S. K., Turner, E. N., Gnant, M. F., and Alexander, H. R. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood, 100: 1334-1339, 2002.

100. Gourgiotis, L., Al-Zubaidi, N., Skarulis, M. C., Papanicolaou, D. A., Libutti, S. K., Alexander Jr, H. R., Merino, M. J., and Sarlis, N. J. Successful Outcome after Surgical Management in Two Cases of the "Painful Variant" of Hashimoto's Thyroiditis. Endocr Pract, 8: 259-265, 2002.

101. Hirshberg, B., Libutti, S. K., Alexander, H. R., Bartlett, D. L., Cochran, C., Livi, A., Chang, R., Shawker, T., Skarulis, M. C., and Gorden, P. Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg, 194: 761-764, 2002.

102. Lans, T. E., Ten Hagen, T. L., Van Horssen, R., Wu, P. C., Van Tiel, S. T., Libutti, S. K., Alexander, H. R., and Eggermont, A. M. Improved Antitumor Response to Isolated Limb Perfusion With Tumor Necrosis Factor After Upregulation of Endothelial Monocyte-Activating Polypeptide II in Soft Tissue Sarcoma. Ann Surg Oncol, 9: 812-819, 2002.

103. Libutti, S. K. and Costouros, N. G. Microarray technology and gene expression analysis for the study of angiogenesis. Expert Opin Biol Ther, 2: 545-556, 2002.

104. Marcos, H. B., Libutti, S. K., Alexander, H. R., Lubensky, I. A., Bartlett, D. L., Walther, M. M., Linehan, W. M., Glenn, G. M., and Choyke, P. L. Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease: Spectrum of Appearances at CT and MR Imaging with Histopathologic Comparison. Radiology, 225: 751-758, 2002.

105. Marx, S. J., Simonds, W. F., Agarwal, S. K., Burns, A. L., Weinstein, L. S., Cochran, C., Skarulis, M. C., Spiegel, A. M., Libutti, S. K., Alexander, H. R., Jr., Chen, C. C., Chang, R., Chandrasekharappa, S. C., and Collins, F. S. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res, 17 Suppl 2: N37-43, 2002.

106. Pautler, S. E., Richards, C., Libutti, S. K., Linehan, W. M., and Walther, M. M. Intentional Resection of the Diaphragm During Cytoreductive Laparoscopic Radical Nephrectomy. J Urol, 167: 48-50., 2002.

107. Sotiriou, C., Powles, T. J., Dowsett, M., Jazaeri, A. A., Feldman, A. L., Assersohn, L., Gadisetti, C., Libutti, S. K., and Liu, E. T. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res, 4: R3, 2002.

108. Wood, B. J., Ramkaransingh, J. R., Fojo, T., Walther, M. M., and Libutti, S. K. Percutaneous tumor ablation with radiofrequency. Cancer, 94: 443-451, 2002.

109. Yu, J., Steiner, F. A., Muench, J. P., Gourgiotis, L., Skarulis, M. C., Altemus, R. M., Libutti, S. K., Merino, M. J., and Sarlis, N. J. Juxtathyroidal neck soft tissue angiosarcoma presenting as an undifferentiated thyroid carcinoma. Thyroid, 12: 427-432, 2002.

110. Zogakis, T. G., Costouros, N. G., Kruger, E. A., Forbes, S., He, M., Qian, M., Feldman, A. L., Figg, W. D., Alexander, H. R., Liu, E. T., Kohn, E. C., and Libutti, S. K. Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay. Biotechniques, 33: 664-666, 668, 670, 2002.

111. Alexander, H. R., Jr., Libutti, S. K., Pingpank, J. F., Steinberg, S. M., Bartlett, D. L., Helsabeck, C., and Beresneva, T. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res, 9: 6343-6349, 2003.

112. Chan, T. J., Libutti, S. K., McCart, J. A., Chen, C., Khan, A., Skarulis, M. K., Weinstein, L. S., Doppman, J. L., Marx, S. J., and Alexander, H. R. Persistent Primary Hyperparathyroidism Caused by Adenomas Identified in Pharyngeal or Adjacent Structures. World J Surg, 2003.

113. Choy, G., O'Connor, S., Diehn, F. E., Costouros, N., Alexander, H. R., Choyke, P., and Libutti, S. K. Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques, 35: 1022-1026, 1028-1030, 2003.

114. Choy, G., Choyke, P., and Libutti, S. K. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging, 2: 303-312, 2003.

115. Elaraj, D. M., Skarulis, M. C., Libutti, S. K., Norton, J. A., Bartlett, D. L., Pingpank, J. F., Gibril, F., Weinstein, L. S., Jensen, R. T., Marx, S. J., and Alexander, H. R. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery, 134: 858-864, 2003.

116. Feldman, A. L., Libutti, S. K., Pingpank, J. F., Bartlett, D. L., Beresnev, T. H., Mavroukakis, S. M., Steinberg, S. M., Liewehr, D. J., Kleiner, D. E., and Alexander, H. R. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol, 21: 4560-4567, 2003.

117. Freedman, N. M., Sundaram, S. K., Kurdziel, K., Carrasquillo, J. A., Whatley, M., Carson, J. M., Sellers, D., Libutti, S. K., Yang, J. C., and Bacharach, S. L. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med Mol Imaging, 30: 46-53, 2003.

118. Hwang, J. J., Uchio, E. M., Pavlovich, C. P., Pautler, S. E., Libutti, S. K., Linehan, W. M., and Walther, M. M. Surgical Management of Multi-Organ Visceral Tumors In Patients With Von Hippel-Lindau Disease: A Single Stage Approach. J Urol, 169: 895-898, 2003.

119. Kayton, M. L., Costouros, N. G., Lorang, D., Alexander, H. R., Hewitt, S. M., Cochran, C., Shalev, A., Harlan, D., Skarulis, M. C., Gorden, P., and Libutti, S. K. Peak stimulated insulin secretion is associated with specific changes in gene expression profiles in sporadic insulinomas. Surgery, 134: 982-987, 2003.

120. Keezer, S. M., Ivie, S. E., Krutzsch, H. C., Tandle, A., Libutti, S. K., and Roberts, D. D. Angiogenesis Inhibitors Target the Endothelial Cell Cytoskeleton through Altered Regulation of Heat Shock Protein 27 and Cofilin. Cancer Res, 63: 6405-6412, 2003.

121. Kurdziel, K. A., Figg, W. D., Carrasquillo, J. A., Huebsch, S., Whatley, M., Sellers, D., Libutti, S. K., Pluda, J. M., Dahut, W., Reed, E., and Bacharach, S. L. Using Positron Emission Tomography 2-Deoxy-2-[18F]Fluoro-D-Glucose, 11CO, and 15O-Water for Monitoring Androgen Independent Prostate Cancer. Mol Imaging Biol, 5: 86-93, 2003.

122. Libutti, S. K., Crabtree, J. S., Lorang, D., Burns, A. L., Mazzanti, C., Hewitt, S. M., O'Connor, S., Ward, J. M., Emmert-Buck, M. R., Remaley, A., Miller, M., Turner, E., Alexander, H. R., Arnold, A., Marx, S. J., Collins, F. S., and Spiegel, A. M. Parathyroid Gland-specific Deletion of the Mouse Men1 Gene Results in Parathyroid Neoplasia and Hypercalcemic Hyperparathyroidism. Cancer Res, 63: 8022-8028, 2003.

123. Lonser, R. R., Glenn, G. M., Walther, M., Chew, E. Y., Libutti, S. K., Linehan, W. M., and Oldfield, E. H. von Hippel-Lindau disease. Lancet, 361: 2059-2067, 2003.

124. Neeman, Z., Libutti, S. K., Patti, J. W., and Wood, B. J. Percutaneous radiofrequency ablation of hepatocellular carcinoma in the presence of portal vein thrombosis. Clin Imaging, 27: 417-420, 2003.

125. Oliver, V. K., Patton, A. M., Desai, S., Lorang, D., Libutti, S. K., and Kohn, E. C. Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole. J Cell Physiol, 197: 139-148, 2003.

126. Pak, H., Gourgiotis, L., Chang, W. I., Guthrie, L. C., Skarulis, M. C., Reynolds, J. C., Merino, M. J., Schrump, D. S., Libutti, S. K., Alexander, H. R., Jr., and Sarlis, N. J. Role of metastasectomy in the management of thyroid carcinoma: The NIH experience. J Surg Oncol, 82: 10-18, 2003.

127. Zogakis, T. G., Gibril, F., Libutti, S. K., Norton, J. A., White, D. E., Jensen, R. T., and Alexander, H. R. Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg, 238: 42-48, 2003.

128. Agarwal, S. K., Lee Burns, A., Sukhodolets, K. E., Kennedy, P. A., Obungu, V. H., Hickman, A. B., Mullendore, M. E., Whitten, I., Skarulis, M. C., Simonds, W. F., Mateo, C., Crabtree, J. S., Scacheri, P. C., Ji, Y., Novotny, E. A., Garrett-Beal, L., Ward, J. M., Libutti, S. K., Richard Alexander, H., Cerrato, A., Parisi, M. J., Santa Anna, A. S., Oliver, B., Chandrasekharappa, S. C., Collins, F. S., Spiegel, A. M., and Marx, S. J. Molecular Pathology of the MEN1 Gene. Ann N Y Acad Sci, 1014: 189-198, 2004.

129. Andrea McCart, J., Mehta, N., Scollard, D., Reilly, R. M., Carrasquillo, J. A., Tang, N., Deng, H., Miller, M., Xu, H., Libutti, S. K., Richard Alexander, H., and Bartlett, D. L. Oncolytic Vaccinia Virus Expressing the Human Somatostatin Receptor SSTR2: Molecular Imaging after Systemic Delivery Using (111)In-Pentetreotide. Mol Ther, 10: 553-561, 2004.

130. Bourdeau, I., Antonini, S. R., Lacroix, A., Kirschner, L. S., Matyakhina, L., Lorang, D., Libutti, S. K., and Stratakis, C. A. Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene, 2004.

131. Feldman, E. D., Wu, P. C., Beresneva, T., Helsabeck, C., Rodriguez, M., Bartlett, D. L., Libutti, S. K., Pingpank, J. F., and Alexander, H. R. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg, 8: 200-207, 2004.

132. Feldman, A. L., Stetler-Stevenson, W. G., Costouros, N. G., Knezevic, V., Baibakov, G., Alexander, H. R., Jr., Lorang, D., Hewitt, S. M., Seo, D. W., Miller, M. S., O'Connor, S., and Libutti, S. K. Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism. Cancer Res, 64: 4481-4486, 2004.

133. Friedman, M., Mikityansky, I., Kam, A., Libutti, S. K., Walther, M. M., Neeman, Z., Locklin, J. K., and Wood, B. J. Radiofrequency ablation of cancer. Cardiovasc Intervent Radiol, 27: 427-434, 2004.

134. Grover, A. C., Libutti, S. K., Pingpank, J. F., Helsabeck, C., Beresnev, T., and Alexander, H. R., Jr. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery, 136: 1176-1182, 2004.

135. Libutti, S. K. Do angiogenesis inhibitors perform a physiologic gatekeeper role in cancer prevention? Cancer J, 10: 12-14, 2004.

136. Martinez, A., Zudaire, E., Portal-Nunez, S., Guedez, L., Libutti, S. K., Stetler-Stevenson, W. G., and Cuttitta, F. Proadrenomedullin NH2-Terminal 20 Peptide Is a Potent Angiogenic Factor, and Its Inhibition Results in Reduction of Tumor Growth. Cancer Res, 64: 6489-6494, 2004.

137. Mazzanti, C., Zeiger, M. A., Costourous, N., Umbricht, C., Westra, W. H., Smith, D., Somervell, H., Bevilacqua, G., Alexander, H. R., and Libutti, S. K. Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors. Cancer Res, 64: 2898-2903, 2004.

138. Mazzanti, C. M., Tandle, A., Lorang, D., Costouros, N., Roberts, D., Bevilacqua, G., and Libutti, S. K. Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells. Genome Res, 14: 1585-1593, 2004.

139. McDonald, D. M., Teicher, B. A., Stetler-Stevenson, W., Ng, S. S., Figg, W. D., Folkman, J., Hanahan, D., Auerbach, R., O'Reilly, M., Herbst, R., Cheresh, D., Gordon, M., Eggermont, A., and Libutti, S. K. Report from the Society for Biological Therapy and Vascular Biology Faculty of the NCI Workshop on Angiogenesis Monitoring. J Immunother, 27: 161-175, 2004.

140. Miller, W. J., Kayton, M. L., Patton, A., O'Connor, S., He, M., Vu, H., Baibakov, G., Lorang, D., Knezevic, V., Kohn, E., Alexander, H. R., Stirling, D., Payvandi, F., Muller, G., and Libutti, S. K. A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assayChorioallantoic Membrane (CAM) Assay. J Transl Med, 2: 4, 2004.

141. Minn, A. H., Kayton, M., Lorang, D., Hoffmann, S. C., Harlan, D. M., Libutti, S. K., and Shalev, A. Insulinomas and expression of an insulin splice variant. Lancet, 363: 363-367, 2004.

142. Sundaram, S. K., Freedman, N. M., Carrasquillo, J. A., Carson, J. M., Whatley, M., Libutti, S. K., Sellers, D., and Bacharach, S. L. Simplified Kinetic Analysis of Tumor 18F-FDG Uptake: A Dynamic Approach. J Nucl Med, 45: 1328-1333, 2004.

143. Tandle, Blazer, I. G., and Libutti, S. K. Antiangiogenic gene therapy of cancer: recent developments. J Transl Med, 2: 22, 2004.

144. Alexander, H. R., Jr., Libutti, S. K., Pingpank, J. F., Bartlett, D. L., Helsabeck, C., and Beresneva, T. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol, 12: 138-144, 2005.

145. Rosen, J. E., Costouros, N. G., Lorang, D., Burns, A. L., Alexander, H. R., Skarulis, M. C., Cochran, C., Pingpank, J. F., Marx, S. J., Spiegel, A. M., and Libutti, S. K. Gland Size Is Associated With Changes in Gene Expression Profiles in Sporadic Parathyroid Adenomas. Ann Surg Oncol, 2005.

146. Tandle, A. T., Mazzanti, C., Alexander, H. R., Roberts, D. D., and Libutti, S. K. Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. Cytokine, 30: 347-358, 2005.

147. Pingpank, J. F., Libutti, S. K., Chang, R., Wood, B. J., Neeman, Z., Kam, A. W., Figg, W. D., Zhai, S., Beresneva, T., Seidel, G. D., and Alexander, H. R. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol, 23: 3465-3474, 2005.

148. Libutti, S. K. Understanding the role of gender in the incidence of thyroid cancer. Cancer J, 11: 104-105, 2005.

149. Hirshberg, B., Cochran, C., Skarulis, M. C., Libutti, S. K., Alexander, H. R., Wood, B. J., Chang, R., Kleiner, D. E., and Gorden, P. Malignant insulinoma. Cancer, 2005.

150. Agarwal, S. K., Kennedy, P. A., Scacheri, P. C., Novotny, E. A., Hickman, A. B., Cerrato, A., Rice, T. S., Moore, J. B., Rao, S., Ji, Y., Mateo, C., Libutti, S. K., Oliver, B., Chandrasekharappa, S. C., Burns, A. L., Collins, F. S., Spiegel, A. M., and Marx, S. J. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res, 37: 369-374, 2005.

151. Rosen J, He M, Umbricht C, Alexander HR, Dackiw AP, Zeiger MA, Libutti SK. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery. 2005 Dec;138(6):1050-6; discussion 1056-7.

152. Grover AC, Skarulis M, Alexander HR, Pingpank JF, Javor ED, Chang R, Shawker T, Gorden P, Cochran C, Libutti SK. A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery. 2005 Dec;138(6):1003-8; discussion 1008.

153. Farma JM, Pingpank JF, Libutti SK, Bartlett DL, Ohl S, Beresneva T, Alexander HR. Limited Survival in Patients With Carcinomatosis From Foregut Malignancies After Cytoreduction and Continuous Hyperthermic Peritoneal Perfusion. J Gastrointest Surg. 2005 Dec 1;9(9):1346-1353.

154. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst. 2006 Feb 15;98(4):255-61.

155. Kwon M, Libutti SK. Advances in understanding angiogenesis through molecular studies.Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):26-32.

156. Grover AC, Tangrea MA, Woodson KG, Wallis BS, Hanson JA, Chuaqui RF, Gillespie, JW, Erickson HS, Bonner RF, Pohida TJ, Emmert-Buck MR, Libutti SK. Tumor-Associated Endothelial Cells Display GSTP1 and RARbeta2 Promoter Methylation in Human Prostate Cancer. J Transl Med. 2006 Mar 2;4(1):13.

157. Koch CA, Brouwers FM, Vortmeyer AO, Tannapfel A, Libutti SK, Zhuang Z, Pacak K, Neumann HP, Paschke R. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer. 2006 May 17;6:131.

158. Libutti SK, Alexander HR Jr. Gastrinoma: sporadic and familial disease. Surg Oncol Clin N Am. 2006 Jul;15(3):479-96.

159. Tang JS, Choy G, Bernardo M, Thomasson D, Libutti SK, Choyke PL. Dynamic contrast-enhanced magnetic resonance imaging in the assessment of early response to tumor necrosis factor alpha in a colon carcinoma model. Invest Radiol. 2006 Sep;41(9):691-6.

160. Sudheendra D, Neeman Z, Kam A, Locklin J, Libutti SK, Wood BJ. Intermittent Hepatic Vein Balloon Occlusion During Radiofrequency Ablation in the Liver. Cardiovasc Intervent Radiol. 2006 Sep 11

161. Wettschureck N, Lee E, Libutti SK, Offermanns S, Robey PG, Spiegel AM. Parathyroid-specific double knockout of Gq- and G11-{alpha} subunits leads to a phenotype resembling germline knockout of the extracellular Ca++-sensing receptor. Mol Endocrinol. 2007 Jan;21(1):274-80. doi: 10.1210/me.2006-0110. Epub 2006 Sep 20. PMID: 16988000.

162. Mittendorf EA, Inabnet WB, Libutti SK, McHenry CR, Demeure MJ. Islet Cell Tumors. Curr Probl Surg. 2006 Oct;43(10):685-765.

163. He M, Rosen J, Mangiameli D, Libutti SK. Cancer development and progression. Adv Exp Med Biol. 2007;593:117-33.

164. Rodriguez-Canales J, Hanson J, Tangrea M, Erickson H, Albert P, Wallis B, Richardson A, Pinto P, Linehan W, Gillespie J, Merino M, Libutti S, Woodson K, Emmert-Buck M, Chuaqui R. Identification of a unique epigenetic sub-microenvironment in prostate cancer. J Pathol. 2007 Mar;211(4):410-9. doi: 10.1002/path.2133. PMID: 17278115.

165. Dromi S, Frenkel V, Luk A, Traughber B, Angstadt M, Bur M, Poff J, Xie J, Libutti SK, Li KC, Wood BJ. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res. 2007 May 1;13(9):2722-7.

166. Teo BK, Seo Y, Bacharach SL, Carrasquillo JA, Libutti SK, Shukla H, Hasegawa BH, Hawkins RA, Franc BL. Partial-Volume Correction in PET: Validation of an Iterative Postreconstruction Method with Phantom and Patient Data. J Nucl Med. 2007 May;48(5):802-10.

167. Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller GW, Stirling DI, Libutti SK. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med. 2007 Jul 18;5(1):38

168. Gamblin TC, Egorin MJ, Zuhowski EG, Lagattuta TF, Herscher LL, Russo A, Libutti SK, Alexander HR, Dedrick RL, Bartlett DL. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemother Pharmacol. 2008 Sep;62(4):647-53. doi: 10.1007/s00280-007-0647-9. Epub 2007 Nov 27. PMID: 18040687.

169. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, Seidel G, Shutack Y, Yuldasheva N, Eugeni M, Bartlett DL, Glenn GM, Middelton L, LinehanWM, Libutti SK. Clinical, genetic and radiographic analysis of 108 patients with vonHippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms(PNETs). Surgery. 2007 Dec;142(6):814-8.

170. Blansfield JA, Caragacianu D, Alexander HR 3rd, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK. Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy. Clin Cancer Res. 2008 Jan 1;14(1):270-80.

171.  Lodish MB, Powell AC, Abu-Asab M, Cochran C, Lenz P, Libutti SK, Pingpank JF, Tsokos M, Gorden P. Insulinoma and Gastrinoma Syndromes from a Single Intrapancreatic Neuroendocrine Tumor. J Clin Endocrinol Metab. 2008 Apr;93(4):1123-8. doi: 10.1210/jc.2007-2449. Epub 2008 Feb 5. PMID: 18252785; PMCID: PMC2291484.

172. Shen H-CJ, Rosen JE, Yang LM, Savage SA, Burns AL, Mateo CM, Agarwal SK, Chandrasekharappa SC, Spiegel AM, Collins FS, Marx SJ, Libutti SK.  Parathyroid tumor development involves deregulation of homeobox genes, Endocrine-Related Cancer (2008) 15 267-275.

173. Norton JA, Venzon DJ, Berna MJ, Alexander HR, Fraker DL, Libutti SK, Marx SJ, Gibril F, Jensen RT. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg. 2008 Mar;247(3):501-10.

174. Henry LR, Solomon NP, Howard R, Gurevich-Uvena J, Horst LB, Coppit G, Orlikoff R, Libutti SK, Shaha AR, Stojadinovic A. The Functional Impact on Voice of Sternothyroid Muscle Division During Thyroidectomy. Ann Surg Oncol. Ann Surg Oncol. 2008 Jul;15(7):2027-33. Epub 2008 May 6.

175. Hadi M, Bacharach SL, Whatley M, Libutti SK, Straus SE, Rao VK, Wesley R, Carrasquillo JA. Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV. Nucl Med Biol. 2008 May;35(4):441-5. doi: 10.1016/j.nucmedbio.2008.02.007. PMID: 18482681.

176. Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y,  Westra WH, Clark DP, Umbricht CB, Libutti SK, Zeiger MA. Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res. 2008 Jun 1;14(11):3327-37. doi: 10.1158/1078-0432.CCR-07-4495. PMID: 18519760; PMCID: PMC3086681.

177. Powell AC, Stratakis CA, Patronas NJ, Steinberg SM, Batista D, Alexander HR, Pingpank JF, Keil M, Bartlett DL, Libutti SK. Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia. Surgery. 2008 Jun;143(6):750-8. doi: 10.1016/j.surg.2008.03.022. PMID: 18549891; PMCID: PMC2601697.

178. Chung JY, Braunschweig T, Williams R, Guerrero N, Hoffmann KM, Kwon M, Song YK, Libutti SK, Hewitt SM. Factors in Tissue Handling and Processing That Impact RNA Obtained From Formalin-fixed, Paraffin-embedded Tissue. J Histochem Cytochem. 2008 Nov;56(11):1033-42. Epub 2008 Aug 18.

179. Kwon M, Hanna E, Lorang D, He M, Quick JS, Adem A, Stevenson C, Chung JY, Hewitt SM, Zudaire E, Esposito D, Cuttitta F, Libutti SK. Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy. Cancer Res. 2008 Sep 15;68(18):7332-41.

180. Staquicini FI, Tandle A, Libutti SK, Sun J, Zigler M, Bar-Eli M, Aliperti F, Pérez EC, Gershenwald JE, Mariano M, Pasqualini R, Arap W, Lopes JD. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res. 2008 Oct 15;68(20):8419-28.

181. Hanna E, Quick J, Libutti SK. The tumour microenvironment: a novel target for cancer therapy. Oral Dis. 2009 Jan;15(1):8-17. Epub 2008 Nov 1.

182. Powell AC, Alexander HR, Pingpank JF, Steinberg SM, Skarulis M, Bartlett DL, Agarwal S, Cochran C, Seidel G, Fraker D, Hughes MS, Jensen RT, Marx SJ, Libutti SK. The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery. 2008 Dec;144(6):878-83; discussion 883-4.

183. Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, Arap W, Adem A, Starker E, Hewitt S, Libutti SK. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha Cancer. 2009 Jan 1;115(1):128-39.

184. Guettier JM, Kam A, Chang R, Skarulis MC, Cochran C, Alexander HR, Libutti SK, Pingpank JF, Gorden P. Localization of Insulinomas to Regions of the Pancreas by Intra-Arterial Calcium Stimulation: The NIH Experience. J Clin Endocrinol Metab. 2009 Apr;94(4):1074-80. doi: 10.1210/jc.2008-1986. Epub 2009 Feb 3. PMID: 19190102; PMCID: PMC2682461.

185. Shen HC, He M, Powell A, Adem A, Lorang D, Heller C, Grover AC, Ylaya K, Hewitt SM, Marx SJ, Spiegel AM, Libutti SK. Recapitulation of Pancreatic Neuroendocrine Tumors in Human Multiple Endocrine Neoplasia Type I Syndrome via Pdx1-Directed Inactivation of Men1. Cancer Res. 2009 Mar 1;69(5):1858-66. doi: 10.1158/0008-5472.CAN-08-3662. Epub 2009 Feb 10. PMID: 19208834; PMCID: PMC3879686.

186. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti SK. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS ONE. 2009;4(3):e4972. Epub 2009 Mar 30.

187. Shen HC, Adem A, Ylaya K, Wilson A, He M, Lorang D, Hewitt SM, Pechhold K, Harlan DM, Lubensky IA, Schmidt LS, Linehan WM, Libutti SK. Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations. PLoS ONE. 2009;4(4):e4897. Epub 2009 Apr 2.

188. Tandle AT, Calvani M, Uranchimeg B, Zahavi D, Melillo G, Libutti SK. Endothelial Monocyte Activating Polypeptide-II Modulates Endothelial Cell Responses by Degrading Hypoxia inducible Factor-1alpha through Interaction with PSMA7, a Component of the Proteasome. Exp Cell Res. 2009 Jul 1;315(11):1850-9. doi: 10.1016/j.yexcr.2009.03.021. Epub 2009 Apr 10. PMID: 19362550.

189. Alexander HR Jr, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM, Helsabeck CB, Beresneva TH. Analysis of Factors Associated with Outcome in Patients Undergoing Isolated Hepatic Perfusion for Unresectable Liver Metastases from Colorectal Cancer. Ann Surg Oncol. 2009 Jul;16(7):1852-9. doi: 10.1245/s10434-009-0482-9. Epub 2009 May 12. PMID: 19434456.

190. Holcomb VB, Keck VA, Barrett JC, Hong J, Libutti SK, Núñez NP. Obesity impairs wound healing in ovariectomized female mice. In Vivo. 2009 Jul-Aug;23(4):515-8.

191. Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK, Tangrea MA. Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Rev Mol Diagn. 2009 Jul;9(5):455-66.

192. Stojadinovic A, Peoples GE, Libutti SK, Henry LR, Eberhardt J, Howard RS, Gur D, Elster EA, Nissan A. Development of a clinical decision model for thyroid nodules. BMC Surg. 2009 Aug 10;9:12. doi: 10.1186/1471-2482-9-12. PMID: 19664278; PMCID: PMC2731077.

193. Meir T, Levi R, Lieben L, Libutti S, Carmeliet G, Bouillon R, Silver J, Naveh-Many T. Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the VDR in parathyroid physiology. Am J Physiol Renal Physiol. 2009 Nov;297(5):F1192-8. doi: 10.1152/ajprenal.00360.2009. Epub 2009 Aug 19. PMID: 19692484.

194. Vu HN, Miller WJ, O'Connor SA, He M, Schafer PH, Payvandi F, Muller GW, Stirling DI, Libutti SK. CC-5079: A Small Molecule with MKP1, Antiangiogenic, and Antitumor Activity. J Surg Res. 2010 Nov;164(1):116-25. doi: 10.1016/j.jss.2009.01.031. Epub 2009 Feb 24. PMID: 19726061.

195. Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009 Sep 15;23(18):2152-65.

196. Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I. Liver Resection for Metastatic Melanoma with Postoperative Tumor-Infiltrating Lymphocyte Therapy. Ann Surg Oncol. 2010 Jan;17(1):163-70. doi: 10.1245/s10434-009-0677-0. Epub 2009 Sep 24. PMID: 19777192; PMCID: PMC6292221.

197. Mathur A, Gorden P, Libutti SK. Insulinoma. Surg Clin North Am. 2009 Oct;89(5):1105-21.

198. Burton ER, Libutti SK. Targeting TNF-alpha for cancer therapy. J Biol. 2009 Oct 23;8(9):85. doi: 10.1186/jbiol189. PMID: 19863762; PMCID: PMC2776910.

199. Alexander HR Jr, Fraker DL, Bartlett DL, Libutti SK, Steinberg SM, Soriano P,  Beresnev T. Analysis of Factors Influencing Outcome in Patients With In-Transit Malignant Melanoma Undergoing Isolated Limb Perfusion Using Modern Treatment Parameters. J Clin Oncol. 2010 Jan 1;28(1):114-8. doi: 10.1200/JCO.2009.23.7511. Epub 2009 Nov 9. PMID: 19901107; PMCID: PMC2799229.

200. Powell AC, Alexander HR, Chang R, Marx SJ, Skarulis M, Pingpank JF, BartlettDL, Hughes M, Weinstein LS, Simonds WF, Collins MF, Shawker T, Chen CC, Reynolds J, Cochran C, Steinberg SM, Libutti SK. Reoperation for parathyroid adenoma: A contemporary experience. Surgery. 2009 Dec;146(6):1144-55. PubMed:19958942.

201. Shen HC, Libutti SK. The Menin Gene. Cancer Treat Res. 2010;153:273-286. PubMed PMID: 19957230.

202. Powell AC, Libutti SK. Multiple endocrine neoplasia type 1: clinical manifestations and management. Cancer Treat Res. 2010;153:287-302. PMID: 19957231.

203. He M, Mangiameli DP, Kachala S, Hunter K, Gillespie J, Bian X, Shen HC, Libutti SK. Expression Signature Developed from a Complex Series of Mouse Models Accurately Predicts Human Breast Cancer Survival. Clin Cancer Res. 2010 Jan 1;16(1):249-59. doi: 10.1158/1078-0432.CCR-09-1602. Epub 2009 Dec 22. PMID: 20028755; PMCID: PMC2866744.

204. Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010 Feb;6(2):229-37. PubMed PMID: 20146582.

205. Powell AC, Paciotti GF, Libutti SK. Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. Methods Mol Biol. 2010;624:375-84. PubMed PMID: 20217609.

206. Shen HC, Ylaya K, Pechhold K, Wilson A, Adem A, Hewitt SM, Libutti SK. Multiple Endocrine Neoplasia Type 1 Deletion in Pancreatic {alpha}-Cells Leads to Development of Insulinomas in Mice. Endocrinology. 2010 Aug;151(8):4024-30. doi: 10.1210/en.2009-1251. Epub 2010 Jun 16. PMID: 20555035; PMCID: PMC2940531.

207. Alsamarai S, Libutti SK, Saif MW. Updates in pancreatic neuroendocrine carcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP. 2010 Jul 5;11(4):336-40. PubMed PMID: 20601807.

208. Mathur A, Kemp CD, Dutta U, Baid S, Ayala A, Chang RE, Steinberg SM, Papademetriou V, Lange E, Libutti SK, Pingpank JF, Alexander HR, Phan GQ, Hughes M, Linehan WM, Pinto PA, Stratakis CA, Kebebew E. Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg. 2010 Sep;211(3):384-90. Epub 2010 Jul 14. PubMed PMID: 20800196; PubMed Central PMCID: PMC2930893.

209. Sreeramoju P, Libutti SK. Strategies for targeting tumors and tumor vasculature for cancer therapy. Adv Genet. 2010;69:135-52. PubMed PMID: 20807606.

210. Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM, Wunderlich J, Alexander HR Jr. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer. 2011 Jan 15;117(2):361-71. doi: 10.1002/cncr.25555. Epub 2010 Sep 13. PMID: 20839315; PMCID: PMC6993181.

211. Libutti SK, Paciotti GF, Byrnes AA, Alexander HR, Gannon WE Jr, Walker M, Seidel GD, Yuldasheva N, Tamarkin L. Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin Cancer Res. 2010 Dec 15;16(24):6139-49. doi: 10.1158/1078-0432.CCR-10-0978. Epub 2010 Sep 27. PMID: 20876255; PMCID: PMC3004980.

212. Libutti SK. Endocrine surgery specialty training: Opportunities for growth. Surgery. 2010 Dec;148(6):1073-4. PubMed PMID: 21134535.

213. Spiegel AM, Libutti SK. Future diagnostic and therapeutic trends in endocrine cancers. Semin Oncol. 2010 Dec;37(6):691-5. Review. PubMed PMID: 21167386.

214. Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, Steinberg SM, Wood BJ, Kammula US, Fojo T, Avital I. Liver Resection and Ablation for Metastatic Adrenocortical Carcinoma. Ann Surg Oncol. 2011 Jul;18(7):1972-9. doi: 10.1245/s10434-011-1564-z. Epub 2011 Feb 8. PMID: 21301973; PMCID: PMC3272672.

215. Rosen JE, Libutti SK, Lee SL. Thyroid Cancer: Molecular and Modern Advances. J Oncol. 2010;2010:317034. Epub 2011 Feb 7. PubMed PMID: 21331370.

216. Citrin D, Camphausen K, Wood BJ, Quezado M, Denobile J, Pingpank JF, Royal RE, Alexander HR, Seidel G, Steinberg SM, Shuttack Y, Libutti SK. A Pilot Feasibility Study of TNFerade™ Biologic with Capecitabine and Radiation Therapy Followed by Surgical Resection for the Treatment of Rectal Cancer. Oncology. 2010;79(5-6):382-8. doi: 10.1159/000323488. Epub 2011 Mar 25. PMID: 21447969; PMCID: PMC3078259.

217. Spiegel AM, Libutti SK. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors. Nat Rev Clin Oncol. 2011 May;8(5):258-9. doi: 10.1038/nrclinonc.2011.50. Epub 2011 Mar 29. PMID: 21448150.

218. Burton ER, Gaffar A, Lee SJ, Adeshuko F, Whitney KD, Chung JY, Hewitt SM, Huang GS, Goldberg GL, Libutti SK, Kwon M. Down-regulation of filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer. Mol Cancer Res. 2011 Aug;9(8):1126-38. doi: 10.1158/1541-7786.MCR-11-0162. Epub 2011 Jun 21. PMID: 21693594; PMCID: PMC3157597.

219. Webb R, Mathur A, Chang R, Baid S, Nilubol N, Libutti SK, Stratakis CA, Kebebew E. What is the Best Criterion for the Interpretation of Adrenal Vein Sample Results in Patients with Primary Hyperaldosteronism? Ann Surg Oncol. 2012 Jun;19(6):1881-6. doi: 10.1245/s10434-011-2121-5. Epub 2011 Nov 3. PMID: 22048631; PMCID: PMC4034057.

220. Kitano M, Millo C, Rahbari R, Herscovitch P, Gesuwan K, Webb RC, Venkatesan AM, Phan GQ, Hughes MS, Libutti SK, Nilubol N, Linehan WM, Kebebew E. Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. Surgery. 2011 Dec;150(6):1122-8. PubMed PMID: 22136831.

221. Prasad N, Kowalski J, Tsai HL, Talbot K, Somervell H, Kouniavsky G, Wang Y, Dackiw A, Westra WH, Clark DP, Libutti SK, Umbricht CB, Zeiger MA. Three-Gene Molecular Diagnostic Model for Thyroid Cancer. Thyroid. 2012 Mar;22(3):275-84. doi: 10.1089/thy.2011.0169. Epub 2012 Jan 26. PMID: 22280184; PMCID: PMC3286810.

222. Wood BJ, Poon RT, Locklin JK, Dreher MR, Ng KK, Eugeni M, Seidel G, Dromi S, Neeman Z, Kolf M, Black CD, Prabhakar R, Libutti SK. Phase I Study of Heat-Deployed Liposomal Doxorubicin during Radiofrequency Ablation for Hepatic Malignancies. J Vasc Interv Radiol. 2012 Feb;23(2):248-255.e7. Epub 2011 Dec 16. PubMed PMID: 22178041; PubMed Central PMCID: PMC3264789.

223. Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK, Fojo T, Schrump DS, Avital I. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol. 2012 Jun 1;105(7):709-13. doi: 10.1002/jso.23015. Epub 2011 Dec 20. PMID: 22189845; PMCID: PMC4136651.

224. Arciero CA, Shiue ZS, Gates JD, Peoples GE, Dackiw AP, Tufano RP, Libutti SK,  Zeiger MA, Stojadinovic A. Preoperative thyroid ultrasound is indicated in patients undergoing parathyroidectomy for primary hyperparathyroidism. J Cancer. 2012;3:1-6. Epub 2011 Nov 25. PubMed PMID: 22211139; PubMed Central PMCID: PMC3245602.

225. Nilubol N, Weinstein L, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E. Preoperative Localizing Studies for Initial Parathyroidectomy in MEN1 Syndrome: Is There Any Benefit? World J Surg. 2012 Jun;36(6):1368-74. doi: 10.1007/s00268-012-1451-1. PMID: 22350475.

226. Weisbrod AB, Liewehr DJ, Steinberg SM, Patterson EE, Libutti SK, Marston Linehan W, Nilubol N, Kebebew E. Association of Type O Blood with Pancreatic Neuroendocrine Tumors in Von Hippel-Lindau Syndrome. Ann Surg Oncol. 2012 Jun;19(6):2054-9. doi: 10.1245/s10434-012-2276-8. Epub 2012 Feb 16. PMID: 22350603; PMCID: PMC7472877.

227. Oberstein PE, Remotti H, Saif MW, Libutti SK. Pancreatic neuroendocrine tumors: entering a new era. JOP. 2012 Mar 10;13(2):169-73. PubMed PMID: 22406593.

228. Yavuz S, Simonds WF, Weinstein LS, Collins MT, Kebebew E, Nilubol N, Phan GQ, Libutti SK, Remaley AT, Van Deventer M, Marx SJ. Sleeping Parathyroid Tumor: Rapid Hyperfunction after Removal of the Dominant Tumor. J Clin Endocrinol Metab. 2012 Jun;97(6):1834-41. doi: 10.1210/jc.2011-3030. Epub 2012 Apr 16. PMID: 22508712; PMCID: PMC3387414.

229. Inchauste SM, Lanier BJ, Libutti SK, Phan GQ, Nilubol N, Steinberg SM, Kebebew E, Hughes MS. Rate of Clinically Significant Postoperative Pancreatic Fistula in Pancreatic Neuroendocrine Tumors. World J Surg. 2012 Jul;36(7):1517-26. doi: 10.1007/s00268-012-1598-9. PMID: 22526042; PMCID: PMC3521612.

230.  Henry L, Helou L, Solomon N, Chang A, Libutti S, Stojadinovic A. Current Practice Patterns Regarding the Conduct of Thyroidectomy and Parathyroidectomy amongst Surgeons - A Survey Study. J Cancer. 2012;3:207-16. Epub 2012 May 12. PubMed PMID: 22606210; PubMed Central PMCID: PMC3354416.

231. Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS. Development and Treatment of Tertiary Hyperparathyroidism in Patients with Pseudohypoparathyroidism Type 1B. J Clin Endocrinol Metab. 2012 Sep;97(9):3025-30. doi: 10.1210/jc.2012-1655. Epub 2012 Jun 26. PMID: 22736772; PMCID: PMC3431579.

232. Weisbrod AB, Nilubol N, Weinstein LS, Simonds WF, Libutti SK, Jensen RT, Marx  SJ, Kebebew E. Association of Type-O Blood with Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. J Clin Endocrinol Metab. 2013 Jan;98(1):E109-14. doi: 10.1210/jc.2012-2781. Epub 2012 Oct 23. PMID: 23093487; PMCID: PMC3537107.

233. Quinn TJ, Yuan Z, Adem A, Geha R, Vrikshajanani C, Koba W, Fine E, Hughes DT, Schmid H, Libutti SK. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1(MEN1) conditional knockout mouse model. Surgery. 2012 Dec;152(6):1068-77. doi: 10.1016/j.surg.2012.08.021. Epub 2012 Oct 24. PMID: 23102680; PMCID: PMC3732168.

234. Turcotte S, Turkbey B, Barak S, Libutti SK, Alexander HR, Linehan WM, Hughes MS, Nilubol N, Gesuwan K, Millo C, Quezado M, Choyke PL, Kebebew E, Phan GQ. von Hippel-Lindau disease-associated solid microcystic serous adenomas masquerading as pancreatic neuroendocrine neoplasms. Surgery. 2012 Dec;152(6):1106-17. doi: 10.1016/j.surg.2012.08.010. Epub 2012 Oct 27. PMID: 23107912; PMCID: PMC3501588.

235. Yuan Z, Syrkin G, Adem A, Geha R, Pastoriza J, Vrikshajanani C, Smith T, Quinn TJ, Alemu G, Cho H, Barrett JC, Arap W, Pasqualini R, Libutti SK. Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity. Cancer Gene Ther. 2013 Jan;20(1):46-56. doi: 10.1038/cgt.2012.83. Epub 2012 Nov 16. PMID: 23154431; PMCID: PMC3534156.

236. Libutti SK, Inabnet WB 3rd. Force or stratagem? Surgery. 2012 Dec;152(6):975-6. doi: 10.1016/j.surg.2012.08.061. PubMed PMID: 23158171.

237. Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US,Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol. 2013 Feb;20(2):555-61. doi: 10.1245/s10434-012-2651-5. Epub 2012 Dec 12. PubMed PMID: 23233234.

238. Stevenson R, Libutti SK, Saif MW. Novel agents in gastroenteropancreatic neuroendocrine tumors. JOP. 2013 Mar 10;14(2):152-4. doi: 10.6092/1590-8577/1470. PubMed PMID: 23474560.

239. Stevenson R, Libutti SK, Saif MW. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors. JOP. 2013 Mar 10;14(2):155-7. doi: 10.6092/1590-8577/1472. PubMed PMID: 23474561.

240. Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, Holtzman M, Hanna N, Turner K, Beresneva T, Zhu Y. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013 Jun;153(6):779-86. doi: 10.1016/j.surg.2013.01.001. Epub 2013 Mar 13. PMID: 23489943; PMCID: PMC3734959.

241. Nilubol N, Weisbrod AB, Weinstein LS, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E. Utility of Intraoperative Parathyroid Hormone Monitoring in Patients with Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism Undergoing Initial Parathyroidectomy. World J Surg. 2013 Aug;37(8):1966-72. doi: 10.1007/s00268-013-2054-1. PMID: 23722465.

242. Libutti SK. Therapy: Blockade of IGF-1R-not effective in neuroendocrine tumours. Nat Rev Endocrinol. 2013 Jul;9(7):389-90. doi: 10.1038/nrendo.2013.109. Epub 2013 Jun 4. PMID: 23732282.

243. Hong CW, Libutti SK, Wood BJ. Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma. Curr Oncol. 2013 Jun;20(3):e274-7. doi: 10.3747/co.20.1266. PubMed PMID: 23737698; PubMed Central PMCID: PMC3671035.

244. Scholl UI, Goh G, Stölting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR, Brady T, Shapiro JR, Loring E, Nelson-Williams C, Libutti SK, Mane S, Hellman P, Westin G, Akerström G, Björklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013 Sep;45(9):1050-4. doi: 10.1038/ng.2695. Epub 2013 Aug 4. PMID: 23913001; PMCID: PMC3876926.

245. Gluick T, Yuan Z, Libutti SK, Marx SJ. Mutation in CDKN2C (p18) and CDKN2D (p19) may cause sporadic parathyroid adenoma. Endocr Relat Cancer. 2013 Nov 6;20(6):L27-9. doi: 10.1530/ERC-13-0445. PMID: 24127162.

246. Libutti SK. Evolving paradigm for managing small nonfunctional incidentally discovered pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2013 Dec;98(12):4670-2. doi: 10.1210/jc.2013-3696. PubMed PMID: 24311793.

247. Kwon M, Lee SJ, Wang Y, Rybak Y, Luna A, Reddy S, Adem A, Beaty BT, Condeelis JS, Libutti SK. Filamin A interacting protein 1-like inhibits WNT signaling and MMP expression to suppress cancer cell invasion and metastasis. Int J Cancer. 2014 Jul 1;135(1):48-60. doi: 10.1002/ijc.28662. Epub 2014 Feb 20. PMID: 24327474; PMCID: PMC3991758.

248. Kwon M, Lee SJ, Reddy S, Rybak Y, Adem A, Libutti SK. Down-Regulation of Filamin A interacting protein 1-like Is Associated with Promoter Methylation and an Invasive Phenotype in Breast, Colon, Lung and Pancreatic Cancers. PLoS One. 2013 Dec 5;8(12):e82620. doi: 10.1371/journal.pone.0082620. PubMed PMID:24340050; PubMed Central PMCID: PMC3855469.

249. Weisbrod AB, Kitano M, Thomas F, Williams D, Gulati N, Gesuwan K, Liu Y, Venzon D, Turkbey I, Choyke P, Yao J, Libutti SK, Nilubol N, Linehan WM, Kebebew E. Assessment of tumor growth in pancreatic neuroendocrine tumors in von hippel lindau syndrome. J Am Coll Surg. 2014 Feb;218(2):163-9.   doi:10.1016/j.jamcollsurg. 2013.10.025. Epub 2013 Nov 12. PubMed PMID: 24440063.

250. Cervera I, Boucai L, Andreopoulou P, Libutti SK, Hughes DT. Referral Patterns for Endocrine Surgical Disease. Endocr Pract. 2014 Jun;20(6):571-5. doi: 10.4158/EP13061.OR. PMID: 24449658.

251. Libutti SK. New horizons for cancer gene therapy. Cancer Gene Ther. 2014 Jan;21(1):1. doi: 10.1038/cgt.2013.80. PubMed PMID: 24492767.

252. Yuan Z, Opas EE, Vrikshajanani C, Libutti SK, Levine MA. Generation of mice encoding a conditional null allele of Gcm2. Transgenic Res. 2014 Aug;23(4):631-41. doi: 10.1007/s11248-014-9799-7. Epub 2014 Apr 16. PMID: 24736975; PMCID: PMC4086301.

253. Vicente DA, Solomon NP, Avital I, Henry LR, Howard RS, Helou LB, Coppit GL, Shriver CD, Buckenmaier CC, Libutti SK, Shaha AR, Stojadinovic A. Voice Outcomes after Total Thyroidectomy, Partial Thyroidectomy, or Non-Neck Surgery         Using a Prospective Multifactorial Assessment. J Am Coll Surg. 2014 Jul;219(1):152-63. doi: 10.1016/j.jamcollsurg.2014.03.019. Epub 2014 Mar 18. PMID: 24745621.

254. Debelenko LV, Agarwal S, Du Q, Yan W, Erickson HS, Abu-Asab M, Raffeld MA, Libutti SK, Marx SJ, Emmert-Buck MR. Menin Immunoreactivity in Secretory Granules of Human Pancreatic Islet Cells. Appl Immunohistochem Mol Morphol. 2014 Nov-Dec;22(10):748-55. doi: 10.1097/PAI.0000000000000046. PMID: 25153502; PMCID: PMC4232475.

255. Kwon M, Libutti SK. Filamin A interacting protein 1-like as a therapeutic target in cancer. Expert Opin Ther Targets. 2014 Dec;18(12):1435-47. doi: 10.1517/14728222.2014.957181. Epub 2014 Sep 9. PMID: 25200207.

256. Cui MH, Branch CA, Cahill SM, Quinn TJ, Adem A, Libutti SK, Yuan Z. In vivo proton MR spectroscopy of pancreatic neuroendocrine tumors in a multiple endocrine neoplasia type 1 conditional knockout mouse model. Magn Reson Med. 2015 Nov;74(5):1221-6. doi: 10.1002/mrm.25529. Epub 2014 Nov 13. PMID: 25392979; PMCID: PMC4430461.

257. Gabizon A, Bradbury M, Prabhakar U, Zamboni W, Libutti S, Grodzinski P. Cancer nanomedicines: closing the translational gap. Lancet. 2014 Dec 20;384(9961):2175-6. doi: 10.1016/S0140-6736(14)61457-4. Epub 2014 Dec 19. PubMed PMID: 25625382.

258. Libutti SK. Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy's smart bombs. Cancer Gene Ther. 2015 Mar;22(2):63. doi: 10.1038/cgt.2015.1. PubMed PMID: 25753044.

259. Del Rivero J, Libutti SK. Invited commentary. Radiographics. 2015 Mar-Apr;35(2):516-8. doi: 10.1148/rg.352140286. PubMed PMID: 25763734.

260. Attarian S, Libutti SK, Chuy J. ACTH-Producing Pancreatic Neuroendocrine Tumor Presenting with Severe Hypokalemic Alkalosis: A Case Report. J Gastrointest Cancer. 2016 Jun;47(2):217-20. doi: 10.1007/s12029-015-9740-1. PMID: 26073616.

261. Shah M, Da Silva R, Gravekamp C, Libutti SK, Abraham T, Dadachova E. Targeted  radionuclide therapies for pancreatic cancer. Cancer Gene Ther. 2015 Aug;22(8):375-9. doi: 10.1038/cgt.2015.32. Epub 2015 Jul 31. Review. PubMed PMID:26227823.

262. Hong CW, Chow L, Turkbey EB, Lencioni R, Libutti SK, Wood BJ. Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors. Cardiovasc Intervent Radiol. 2016 Mar;39(3):409-16. doi: 10.1007/s00270-015-1186-0. Epub 2015 Jul 31. PMID: 26228246; PMCID: PMC4733610.

263. Rosenberg AM, Friedmann P, Del Rivero J, Libutti SK, Laird AM. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors. Surgery. 2016 Jan;159(1):302-9. doi: 10.1016/j.surg.2015.10.013. Epub 2015 Nov 4. PMID: 26547726.

264. Laird AM, Libutti SK. Minimally Invasive Parathyroidectomy Versus Bilateral Neck Exploration for Primary Hyperparathyroidism. Surg Oncol Clin N Am. 2016 Jan;25(1):103-18. doi: 10.1016/j.soc.2015.08.012. Review. PubMed PMID: 26610777.

265. Libutti SK. Navigating the regulatory road to approval for cancer gene therapies.          Cancer Gene Ther. 2015 Dec;22(12):553. doi: 10.1038/cgt.2015.62. PubMed PMID: 26658519.

266. McKimpson WM, Yuan Z, Zheng M, Crabtree JS, Libutti SK, Kitsis RN. The Cell Death Inhibitor ARC Is Induced in a Tissue-Specific Manner by Deletion of the Tumor Suppressor Gene Men1, but Not Required for Tumor Development and Growth. PLoS One. 2015 Dec 28;10(12):e0145792. doi: 10.1371/journal.pone.0145792. eCollection 2015. PubMed PMID: 26709830.

267. Assadipour Y, Azoury SC, Schaub NN, Hong Y, Eil R, Inchauste SM, Steinberg SM, Venkatesan AM, Libutti SK, Hughes MS. Significance of preoperative radiographic pancreatic density in predicting pancreatic fistula after surgery for pancreatic neuroendocrine tumors. Am J Surg. 2016 Jul;212(1):40-6. doi: 10.1016/j.amjsurg.2015.07.031. Epub 2015 Dec 12. PMID: 26782807; PMCID: PMC7480190.

268. Serrano OK, Huang K, Ng N, Yang J, Friedmann P, Libutti SK, Kennedy TJ. Correlation between preoperative endoscopic ultrasound and surgical pathology staging of gastric adenocarcinoma: A single institution retrospective review. J Surg Oncol. 2016 Jan;113(1):42-5. doi: 10.1002/jso.24098. Epub 2016 Jan 19. PubMed PMID: 26784562.

269. Fazio N, Buzzoni R, Baudin E, Antonuzzo L, Hubner RA, Lahner H, DE Herder WW, Raderer M, Teulé A, Capdevila J, Libutti SK, Kulke MH, Shah M, Dey D, Turri S, Aimone P, Massacesi C, Verslype C. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Res. 2016 Feb;36(2):713-9. PubMed PMID: 26851029.

270. Dondossola E, Dobroff AS, Marchiò S, Cardó-Vila M, Hosoya H, Libutti SK, Corti A, Sidman RL, Arap W, Pasqualini R. Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2223-8. doi: 10.1073/pnas.1525697113. Epub 2016 Feb 8. PMID: 26858439; PMCID: PMC4776485.

271. Yuan Z, Claros CS, Suzuki M, Maggi EC, Kaner JD, Kinstlinger N, Gorecka J, Quinn TJ, Geha R, Corn A, Pastoriza J, Jing Q, Adem A, Wu H, Alemu G, Du YC, Zheng D, Greally JM, Libutti SK. Loss of MEN1 activates DNMT1 implicating DNA hypermethylation as a driver of MEN1 tumorigenesis. Oncotarget. 2016 Mar 15;7(11):12633-50. doi: 10.18632/oncotarget.7279. PMID: 26871472; PMCID: PMC4914310.

272. Smith TL, Yuan Z, Cardó-Vila M, Sanchez Claros C, Adem A, Cui MH, Branch CA, Gelovani JG, Libutti SK, Sidman RL, Pasqualini R, Arap W. AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas. Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):2466-71. doi: 10.1073/pnas.1525709113. Epub 2016 Feb 16. PMID: 26884209; PMCID: PMC4780640.

273. Keutgen XM, Hammel P, Choyke PL, Libutti SK, Jonasch E, Kebebew E. Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. Nat Rev Clin Oncol. 2016 Sep;13(9):537-49. doi: 10.1038/nrclinonc.2016.37. Epub 2016 Mar 31. PMID: 27030075.

274. Serrano OK, Love C, Goldman I, Huang K, Ng N, Abraham T, Da Silva R, Friedmann P, Libutti SK, Kennedy TJ. The value of FDG-PET in the staging of gastricadenocarcinoma: A single institution retrospective review. J Surg Oncol. 2016 May;113(6):640-6. doi: 10.1002/jso.24190. PubMed PMID: 27115836.

275. Kwon M, Kim JH, Rybak Y, Luna A, Hun Choi C, Chung JY, Hewitt SM, Adem A,Tubridy E, Lin J, Libutti SK. Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer. Oncotarget. 2016 Nov 22;7(47):77052-77070. doi: 10.18632/oncotarget.12784. PMID: 27776341; PMCID: PMC5340232.

276. Libutti SK. Editorial: Treatment decision making in the era of genetic testing and molecular diagnostics. Surgery. 2017 Jan;161(1):228-229. doi: 10.1016/j.surg.2016.        10.009. PubMed PMID: 27863788.

277. Libutti SK. Of mice and men(in) and what I have learned from both. Surgery. 2017         Jan;161(1):1-11. doi: 10.1016/j.surg.2016.10.004. PubMed PMID: 27865595.

278. Chandra D, Selvanesan BC, Yuan Z, Libutti SK, Koba W, Beck A, Zhu K, Casadevall A, Dadachova E, Gravekamp C. 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. Oncotarget. 2017 Mar 28;8(13):20729-20740. doi: 10.18632/oncotarget.15117. PMID: 28186976; PMCID: PMC5400540.

279. Frank SJ, Goldman-Yassen AE, Koenigsberg T, Libutti SK, Koenigsberg M. Sensitivity of 3-Dimensional Sonography in Preoperative Evaluation of Parathyroid Glands in Patients With Primary Hyperparathyroidism. J Ultrasound Med. 2017 Sep;36(9):1897-1904. doi: 10.1002/jum.14245. Epub 2017 May 24. PMID: 28543268.

280. Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N. RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology. 2018;106(3):211-220. doi: 10.1159/000477585. Epub 2017 May 24. PMID: 28554173.

281. Wang H, Bender A, Wang P, Karakose E, Inabnet WB, Libutti SK, Arnold A, Lambertini L, Stang M, Chen H, Kasai Y, Mahajan M, Kinoshita Y, Fernandez-Ranvier G, Becker TC, Takane KK, Walker LA, Saul S, Chen R, Scott DK, Ferrer J, Antipin Y, Donovan M, Uzilov AV, Reva B, Schadt EE, Losic B, Argmann C, Stewart AF. Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas. Nat Commun. 2017 Oct 3;8(1):767. doi: 10.1038/s41467-017-00992-9. PubMed PMID: 28974674.

282. Tirosh A, Sadowski SM, Linehan WM, Libutti SK, Patel D, Nilubol N, Kebebew E. Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease. JAMA Oncol. 2018 Jan 1;4(1):124-126. doi: 10.1001/jamaoncol.2017.3428. PubMed PMID: 29075773.

283. Snyder SK, Angelos P, Carty SE, Doherty GM, Howe JR, Lee JA, Libutti SK, Miller BS, Parangi S, Patel KN, Sippel RC, Sturgeon C, Wang TS, Yip L, Zeiger MA. Injection of bulking agents for laryngoplasty. Surgery. 2018 Jan;163(1):6-8. doi: 10.1016/ j.surg.2017.08.019. Epub 2017 Nov 9. PubMed PMID: 29129367.

284. Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande     E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC. Phase II Study of  BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144. Epub 2017 Dec 14. PMID: 29242283; PMCID: PMC6058330.

285. Maggi EC, Gravina S, Cheng H, Piperdi B, Yuan Z, Dong X, Libutti SK, Vijg J, Montagna C. Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model. Front Genet. 2018 Jan 23;9:6. doi: 10.3389/fgene.2018.00006. eCollection 2018. PubMed PMID: 29410677.

286. Nilubol N, Yuan Z, Paciotti GF, Tamarkin L, Sanchez C, Gaskins K, Freedman EM, Cao S, Zhao J, Kingston DGI, Libutti SK, Kebebew E. Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors. J Natl Cancer Inst. 2018 Sep 1;110(9):1019-1029. doi: 10.1093/jnci/djy003. PMID: 29481652; PMCID: PMC6136933.

287. Zhao Z, Kantamneni H, He S, Pelka S, Venkataraman AS, Kwon M, Libutti SK, Pierce M, Moghe PV, Ganapathy V, Tan MC. Surface-Modified Shortwave-Infrared-Emitting Nanophotonic Reporters for Gene-Therapy Applications. ACS Biomater Sci Eng. 2018 Jul 9;4(7):2305-2363. doi: 10.1021/acsbiomaterials.8b00378. Epub 2018 Apr 30. PMID: 30417087; PMCID: PMC6226244.

288. Aijaz A, Li M, Smith D, Khong D, LeBlon C, Fenton OS, Olabisi RM, Libutti S, Tischfield J, Maus MV, Deans R, Barcia RN, Anderson DG, Ritz J, Preti R, Parekkadan B. Biomanufacturing for clinically advanced cell therapies. Nat Biomed Eng. 2018 Jun;2(6):362-376. doi: 10.1038/s41551-018-0246-6. Epub 2018 Jun 11. Review. PMID: 31011198. PMCID: PMC6594100.

289. Faustino LC, Lombardi A, Madrigal-Matute J, Owen RP, Libutti SK, Tomer Y. Interferon Alpha Triggers Autoimmune Thyroid Diseases via Lysosomal-Dependent Degradation of Thyroglobulin. J Clin Endocrinol Metab. 2018 Oct 1;103(10):3678-3687. doi: 10.1210/jc.2018-00541. PMID: 30113675; PMCID: PMC6179164.

290. Yuan Z, Gardiner JC, Maggi EC, Adem A, Zhang G, Lee S, Romanienko P, Du YN, Libutti SK. Tissue-specific induced DNA methyltransferase 1 (Dnmt1) in endocrine pancreas by RCAS-TVA-based somatic gene transfer system promotes β-cell proliferation. Cancer Gene Ther. 2019 Mar;26(3-4):94-102. doi: 10.1038/s41417-018-0046-x. Epub 2018 Sep 7. PMID: 30190513; PMCID: PMC7540611.

291. Libutti SK, Tamarkin L, Nilubol N. Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure. Oncotarget. 2018 Nov 6;9(87):35723-35725. doi: 10.18632/oncotarget.26267. eCollection 2018 Nov 6. PMID: 30515264. PMCID: PMC6254664.

292. Maker AV, Tran TB, Coburn N, Fong ZV, Cardona K, Newell P, Morris-Stiff G, Chavin K, Mansour J; members of the AHPBA Research Committee Consensus Conference. Collaborators: Warner S, Warren R, St Hill C, Celinski S, Ly Q, Howe J, Libutti S. Does attending a Delphi consensus conference impact surgeon attitudes? Survey results from the Americas HepatoPancreatoBiliary Association consensus conference on small asymptomatic pancreatic neuroendocrine tumors. HPB (Oxford). 2019 May;21(5):524-530. doi: 10.1016/j.hpb.2018.10.001. Epub 2018 Nov 13. PMID: 30442562.

293. Mansour JC, Chavin K, Morris-Stiff G, Warner SG, Cardona K, Fong ZV, Maker A, Libutti SK, Warren R, St Hill C, Celinski S, Newell P, Ly QP, Howe J, Coburn N. Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association. HPB (Oxford). 2019 May;21(5):515-523. doi: 10.1016/j.hpb.2018.09.020. Epub 2018 Dec 5. PMID: 30527517.

294. Bresler A, Mehta V, Schiff BA, Smith RV, Khader S, Ramos-Rivera G, Lin J, Libutti SK, Laird AM, Ow TJ. Comparison of Bethesda cytopathology classification to surgical pathology across racial-ethnic groups. Head Neck. 2019 Jul;41(7):2340-2345. doi: 10.1002/hed.25707. Epub 2019 Feb 21. PMID: 30793405.

295. Stein MN, Malhotra J, Tarapore RS, Malhotra U, Silk AW, Chan N, Rodriguez L, Aisner J, Aiken RD, Mayer T, Haffty BG, Newman JH, Aspromonte SM, Bommareddy PK, Estupinian R, Chesson CB, Sadimin ET, Li S, Medina DJ, Saunders T, Frankel M, Kareddula A, Damare S, Wesolowsky E, Gabel C, El-Deiry WS, Prabhu VV, Allen JE, Stogniew M, Oster W, Bertino JR, Libutti SK, Mehnert JM, Zloza A. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. J Immunother Cancer. 2019 May 22;7(1):136. doi: 10.1186/s40425-019-0599-8. PMID:  31118108. PMCID: PMC6532211.

296. Staquicini FI, Smith TL, Tang FHF, Gelovani JG, Giordano RJ, Libutti SK, Sidman RL, Cavenee WK, Arap W, Pasqualini R. Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies. Cancer Gene Ther. 2020 May;27(5):301-310. doi: 10.1038/s41417-019-0101-2. Epub 2019 May 27. PMID: 31130731; PMCID: PMC6879804.

297. Libutti SK. Recording 25 years of progress in Cancer Gene Therapy. Cancer Gene Ther. 2019 Nov;26(11-12):345-346. doi: 10.1038/s41417-019-0121-y. Epub 2019 Jul 9. PMID: 31285540.

298. Chi A, Adams BE, Sesti J, Paul S, Turner AL, August D, Carpizo D, Kennedy T, Grandhi M, Alexander HR, Libutti SK, Geffner S, Langan RC. Outcomes Following Major Oncologic Operations for Non-AIDS-Defining Cancers in the HIV Population: A Matched Comparison to the General Population. World J Surg. 2019 Dec;43(12):3019-3026. doi: 10.1007/s00268-019-05151-3. PMID: 31493193.

299. Libutti SK. Early-stage pancreatic neuroendocrine tumors (PNETs): Patience is a virtue. Surgery. 2020 Jan;167(1):187-188. doi: 10.1016/j.surg.2019.08.015. Epub 2019 Oct 22. PMID: 31653490.

300. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020 Jan;49(1):1-33. doi: 10.1097/MPA.0000000000001454. PMID: 31856076; PMCID: PMC7029300.

301. Laird AM, Libutti SK. Management of Other Gastric and Duodenal Neuroendocrine Tumors. Surg Oncol Clin N Am. 2020 Apr;29(2):253-266. doi: 10.1016/j.soc.2019.11.009. Review. PMID: 32151359.

302. Hwang ES, Balch CM, Balch GC, Feldman SM, Golshan M, Grobmyer SR, Libutti SK, Margenthaler JA, Sasidhar M, Turaga KK, Wong SL, McMasters KM, Tanabe KK. Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change. Ann Surg Oncol. 2020 Aug;27(8):2600-2613. doi: 10.1245/s10434-020-08673-6. Epub 2020 Jun 14. PMID: 32535870; PMCID: PMC7293588.

303. Yeung A, Friedmann P, In H, Bloomgarden N, McAuliffe JC, Libutti SK, Laird AM. Evaluation of Adrenal Vein Sampling Use and Outcomes in Patients With Primary Aldosteronism. J Surg Res. 2020 Aug 19;256:673-679. doi: 10.1016/j.jss.2020.05.099. Epub ahead of print. PMID: 32827833.

304. Karakose E, Wang H, Inabnet W, Thakker RV, Libutti S, Fernandez-Ranvier G, Suh H, Stevenson M, Kinoshita Y, Donovan M, Antipin Y, Li Y, Liu X, Jin F, Wang P, Uzilov A, Argmann C, Schadt EE, Stewart AF, Scott DK, Lambertini L. Aberrant methylation underlies insulin gene expression in human insulinoma. Nat Commun. 2020 Oct 15;11(1):5210. doi: 10.1038/s41467-020-18839-1. PMID: 33060578; PMCID: PMC7566641.

305. Yuan Z, Gardiner JC, Maggi EC, Huang S, Adem A, Bagdasarov S, Li G, Lee S, Slegowski D, Exarchakis A, Howe JR, Lattime EC, Zang X, Libutti SK. B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors. Endocr Relat Cancer. 2021 Jan 1:ERC-20-0337.R1. doi: 10.1530/ERC-20-0337. Epub ahead of print. PMID: 33410766.

306. Romero-Velez G, Laird AM, Barajas ME, Sierra-Salazar M, Herrera MF, Libutti SK, Parides MK, Pereira X, McAuliffe JC. Outcomes of Adrenalectomy and the Aldosteronoma Resolution Score in the Black and Hispanic Population. World J Surg. 2021 Feb 7. doi: 10.1007/s00268-021-05967-y. Epub ahead of print. PMID: 33554297.

307. Shah MR, Jan I, Johns J, Singh K, Kumar P, Belarmino N, Saggiomo KJ, Hayes C, Washington K, Toppmeyer DL, Haffty BG, Libutti SK, Evens AM. SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center. Cancer. 2021 Feb 18. doi: 10.1002/cncr.33453. Epub ahead of print. PMID: 33599303.

308. Zhang X, Wang X, Yuan Z, Radford SJ, Liu C, Libutti SK, Zheng XFS. Amino acids-Rab1A-mTORC1 signaling controls whole-body glucose homeostasis. Cell Rep. 2021 Mar 16;34(11):108830. doi: 10.1016/j.celrep.2021.108830. PMID: 33730578; PMCID: PMC8062038.

309. Staquicini DI, Tang FHF, Markosian C, Yao VJ, Staquicini FI, Dodero-Rojas E, Contessoto VG, Davis D, O'Brien P, Habib N, Smith TL, Bruiners N, Sidman RL, Gennaro ML, Lattime EC, Libutti SK, Whitford PC, Burley SK, Onuchic JN, Arap W, Pasqualini R. Design and proof-of-concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain. bioRxiv [Preprint]. 2021 Mar 16:2021.03.15.435496. doi: 10.1101/2021.03.15.435496. PMID: 33758865; PMCID: PMC7987025.

310. Datta P, Ukey R, Bruiners N, Honnen W, Carayannopoulos MO, Reichman C, Choudhary A, Onyuka A, Handler D, Guerrini V, Mishra PK, Dewald HK, Lardizabal A, Lederer L, Leiser AL, Hussain S, Jagpal SK, Radbel J, Bhowmick T, Horton DB, Barrett ES, Xie YL, Fitzgerald-Bocarsly P, Weiss SH, Woortman M, Parmar H, Roy J, Dominguez-Bello MG, Blaser MJ, Carson JL, Panettieri RA, Libutti SK, Raymond HF, Pinter A, Gennaro ML. Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection. medRxiv [Preprint]. 2021 Jul 14:2021.07.09.21260266. doi: 10.1101/2021.07.09.21260266. PMID: 34282427; PMCID: PMC8288160.

311. Staquicini DI, Tang FHF, Markosian C, Yao VJ, Staquicini FI, Dodero-Rojas E, Contessoto VG, Davis D, O'Brien P, Habib N, Smith TL, Bruiners N, Sidman RL, Gennaro ML, Lattime EC, Libutti SK, Whitford PC, Burley SK, Onuchic JN, Arap W, Pasqualini R. Design and proof of concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain. Proc Natl Acad Sci U S A. 2021 Jul 27;118(30):e2105739118. doi: 10.1073/pnas.2105739118. PMID: 34234013; PMCID: PMC8325333.

312. Kwon M, Rubio G, Nolan N, Auteri P, Volmar JA, Adem A, Javidian P, Zhou Z, Verzi MP, Pine SR, Libutti SK. FILIP1L loss is a driver of aggressive mucinous colorectal adenocarcinoma and mediates cytokinesis defects through PFDN1. Cancer Res. 2021 Aug 20:canres.0897.2021. doi: 10.1158/0008-5472.CAN-21-0897. Epub ahead of print. PMID: 34417201; PMCID: PMC8563430.

313. Shoemaker RH, Panettieri RA, Libutti SK, Hochster HS, Watts NR, Wingfield PT, Starkl P, Pimenov L, Gawish R, Hladik A, Knapp S, Boring D, White JM, Lawrence Q, Boone J, Marshall JD, Matthews RL, Cholewa BD, Richig JW, Chen BT, McCormick DL, Gugensberger R, Höller S, Penninger JM, Wirnsberger G. Development of a novel, pan-variant aerosol intervention for COVID-19. bioRxiv [Preprint]. 2021 Sep 14:2021.09.14.459961. doi: 10.1101/2021.09.14.459961. PMID: 34545364; PMCID: PMC8452093.

314. Datta P, Ukey R, Bruiners N, Honnen W, Carayannopoulos MO, Reichman C, Choudhary A, Onyuka A, Handler D, Guerrini V, Mishra PK, Dewald HK, Lardizabal A, Lederer L, Leiser AL, Hussain S, Jagpal SK, Radbel J, Bhowmick T, Horton DB, Barrett ES, Xie YL, Fitzgerald-Bocarsly P, Weiss SH, Woortman M, Parmar H, Roy J, Dominguez-Bello MG, Blaser MJ, Carson JL, Panettieri RA Jr, Libutti SK, Raymond HF, Pinter A, Gennaro ML. Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination. J Immunol Methods. 2021 Dec;499:113165. doi: 10.1016/j.jim.2021.113165. Epub 2021 Oct 9. PMID: 34634317; PMCID: PMC8500840.

315. Markosian C, Staquicini DI, Dogra P, Dodero-Rojas E, Tang FHF, Smith TL, Contessoto VG, Libutti SK, Wang Z, Cristini V, Whitford PC, Burley SK, Onuchic JN, Pasqualini R, Arap W. Apropos of Universal Epitope Discovery for COVID-19 Vaccines: A Framework for Targeted Phage Display-Based Delivery and Integration of New Evaluation Tools. bioRxiv [Preprint]. 2021 Aug 30:2021.08.30.458222. doi: 10.1101/2021.08.30.458222. PMID: 34676381; PMCID: PMC8529634.

316. Butner JD, Martin GV, Wang Z, Corradetti B, Ferrari M, Esnaola N, Chung C, Hong DS, Welsh JW, Hasegawa N, Mittendorf EA, Curley SA, Chen SH, Pan PY, Libutti SK, Ganesan S, Sidman RL, Pasqualini R, Arap W, Koay EJ, Cristini V. Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. Elife. 2021 Nov 9;10:e70130. doi: 10.7554/eLife.70130. PMID: 34749885; PMCID: PMC8629426.

317. Gonda A, Zhao N, Shah JV, Siebert JN, Gunda S, Inan B, Kwon M, Libutti SK, Moghe PV, Francis NL, Ganapathy V. Extracellular Vesicle Molecular Signatures Characterize Metastatic Dynamicity in Ovarian Cancer. Front Oncol. 2021 Nov 18;11:718408. doi: 10.3389/fonc.2021.718408. PMID: 34868914; PMCID: PMC8637407.

318. Bruiners N, Guerrini V, Ukey R, Dikdan R, Yang J, Mishra PK, Onyuka A, Handler D, Vieth J, Carayannopulos M, Guo S, Pollen M, Pinter A, Tyagi S, Feingold D, Philipp C, Libutti S, Gennaro ML. Biologic correlates of beneficial convalescent plasma therapy in a COVID-19 patient reveal disease resolution mechanisms. medRxiv [Preprint]. 2022 Feb 3:2022.02.03.22269612. doi: 10.1101/2022.02.03.22269612. PMID: 35132422; PMCID: PMC8820674.

319. Selvanesan BC, Chandra D, Quispe-Tintaya W, Jahangir A, Patel A, Meena K, Alves Da Silva RA, Friedman M, Gabor L, Khouri O, Libutti SK, Yuan Z, Li J, Siddiqui S, Beck A, Tesfa L, Koba W, Chuy J, McAuliffe JC, Jafari R, Entenberg D, Wang Y, Condeelis J, DesMarais V, Balachandran V, Zhang X, Lin K, Gravekamp C. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Sci Transl Med. 2022 Mar 23;14(637):eabc1600. doi: 10.1126/scitranslmed.abc1600. Epub 2022 Mar 23. PMID: 35320003.

320. Markosian C, Staquicini DI, Dogra P, Dodero-Rojas E, Lubin JH, Tang FHF, Smith TL, Contessoto VG, Libutti SK, Wang Z, Cristini V, Khare SD, Whitford PC, Burley SK, Onuchic JN, Pasqualini R, Arap W. Genetic and Structural Analysis of SARS-CoV-2 Spike Protein for Universal Epitope Selection. Mol Biol Evol. 2022 May 3:msac091. doi: 10.1093/molbev/msac091. Epub ahead of print. PMID: 35511693.

321. Fan J, Yuan Z, Burley SK, Libutti SK, Zheng XFS. Amino acids control blood glucose levels through mTOR signaling. Eur J Cell Biol. 2022 May 19;101(3):151240. doi: 10.1016/j.ejcb.2022.151240. Epub ahead of print. PMID: 35623230.

322. Bruiners N, Guerrini V, Ukey R, Dikdan RJ, Yang JH, Mishra PK, Onyuka A, Handler D, Vieth J, Carayannopoulos M, Guo S, Pollen M, Pinter A, Tyagi S, Feingold D, Philipp C, Libutti SK, Gennaro ML. Longitudinal Analysis of Biologic Correlates of COVID-19 Resolution: Case Report. Front Med (Lausanne). 2022 Jun 15;9:915367. doi: 10.3389/fmed.2022.915367. PMID: 35783607; PMCID: PMC9240225.

323. Shoemaker RH, Panettieri RA Jr, Libutti SK, Hochster HS, Watts NR, Wingfield PT, Starkl P, Pimenov L, Gawish R, Hladik A, Knapp S, Boring D, White JM, Lawrence Q, Boone J, Marshall JD, Matthews RL, Cholewa BD, Richig JW, Chen BT, McCormick DL, Gugensberger R, Höller S, Penninger JM, Wirnsberger G. Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer. PLoS One. 2022 Jul 11;17(7):e0271066. doi: 10.1371/journal.pone.0271066. PMID: 35816490; PMCID: PMC9273060.

324. Xie S, Kuriakose J, Beninato T, Carayannopoulos M, Trooskin SZ, Libutti SK, Laird AM. Association of Implementation of Operating Room-based Parathyroid Hormone Testing with Operative Time and Cost. J Am Coll Surg. 2022 Aug 19. doi: 10.1097/XCS.0000000000000362. Epub ahead of print. PMID: 36102508.

325. Kwon M, Rubio G, Wang H, Riedlinger G, Adem A, Zhong H, Slegowski D, Post-Zwicker L, Chidananda A, Schrump DS, Pine SR, Libutti SK. Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis. Cancer Res Commun. 2022 Oct 18;2(10):1197-1213. doi: 10.1158/2767-9764.CRC-22-0233. PMID: 36860703; PMCID: PMC9973389.

326. Rajdev L, Lee JW, Libutti SK, Benson AB, Fisher GA Jr, Kunz PL, Hendifar AE, Catalano P, O'Dwyer PJ. A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161. Invest New Drugs. 2022 Dec;40(6):1306-1314. doi: 10.1007/s10637-022-01311-w. Epub 2022 Oct 20. PMID: 36264382; PMCID: PMC9795724.

327. Singla A, Dadario NB, Singla A, Greenberg P, Yan R, Nanda A, Boison D, Malhotra R, Patel S, Nipun S, Maninderpal K, Castro D, Bdiiwi S, Boktor H, Kyi HH, Sutherland A, Patrawalla A, Ly K, Xie Y, Sonig A, Khandelwal P, Liu J, Koziol J, Finkle D, Subanna S, Libutti SK. A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection. PLoS One. 2023 Jan 30;18(1):e0274243. doi: 10.1371/journal.pone.0274243. PMID: 36716303; PMCID: PMC9886260.

328. Kinney AY, Stroup AM, Scharf S, Libutti SK. Rutgers Cancer Institute of New Jersey's Community Outreach and Engagement Approach to Cancer Prevention. Cancer Prev Res (Phila). 2023 Nov 1;16(11):595-600. doi: 10.1158/1940-6207.CAPR-23-0293. PMID: 37908146.

329. Davis CH, Laird AM, Libutti SK. Resistant gastroenteropancreatic neuroendocrine tumors: a definition and guideline to medical and surgical management. Proc (Bayl Univ Med Cent). 2023 Dec 20;37(1):104-110. doi: 10.1080/08998280.2023.2284039. PMID: 38174011; PMCID: PMC10761146.

Back to top